2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Tba6,Plaque psoriasis (PsO) is an inflammatory skin disease that can impair quality of life. Tildrakizumab, an anti-IL-23 p19 monoclonal antibody, offers a treatment option for patients eligible for systemic therapy or phototherapy, but real-world results have not been comprehensively analyzed. This systematic review and meta-analysis evaluated real-world effectiveness, quality-of-life impact, and safety of tildrakizumab for treatment of moderate-to-severe plaque PsO, alone and relative to guselkumab and risankizumab. MEDLINE® and Embase were searched on November 16, 2023, along with meeting abstracts (2021-2023) and bibliographies of previous reviews, for English-language real-world studies of tildrakizumab (singly or comparative) in adults with chronic moderate-to-severe plaque PsO. Outcomes included effectiveness (Psoriasis Area and Severity Index [PASI], Physician's Global Assessment [PGA], body surface area percentage [%BSA] affected), Dermatology Life Quality Index (DLQI), and safety (adverse events [AEs], serious AEs [SAEs], treatment-related AEs [TRAEs], or withdrawals due to AEs [WDAEs]). Meta-analyses were performed at 12-16, 24-28, and 36-52 weeks. Of 6982 records screened, 37 studies (45 publications) were analyzed. Tildrakizumab-treated patients experienced 78-87% improvement from baseline to 36-52 weeks across mean absolute PASI (12.81 [95% confidence interval 11.69, 13.92] to 1.62 [1.03, 2.20]), %BSA (16.21% [13.72%, 18.70%] to 3.27% [1.26%, 5.28%]), PGA (3.18 [2.89, 3.47] to 0.70 [0.08, 1.33]), and DLQI (14.59 [12.32, 16.87] to 1.83 [0.84, 2.82]), with low rates of AEs, SAEs, TRAEs, and WDAEs. Benefits and safety of tildrakizumab were similar to guselkumab and risankizumab. Tildrakizumab demonstrated effectiveness, with reduction from moderate-to-severe to mild disease and improved DLQI scores, without notable safety concerns, for up to 1 year in this real-world meta-analysis. Although real-world data must be interpreted cautiously because of heterogeneity and potential bias, these findings align with randomized trial results, further supporting the use of tildrakizumab in clinical practice. Plaque psoriasis is a chronic skin condition with several treatment options, including tildrakizumab, an antibody approved to treat moderate-to-severe plaque psoriasis in adults. The efficacy and safety of tildrakizumab were first established in clinical trials, but because clinical trials are conducted under ideal conditions, results in real-world practice may be different. This study reviewed and analyzed results from published studies outside of clinical trial settings. These real-world studies provide insight into how tildrakizumab works in everyday clinical practice. The findings from this study showed that tildrakizumab treatment is associated with continued effectiveness over time, improvements in skin-related quality of life, and no new or unexpected safety concerns in patients with moderate-to-severe plaque psoriasis.31:T4ef,Scott Gottlieb serves as a consultant and advisory board member for Bristol Myers Squibb, Janssen, Lilly, Sun Pharmaceutical Industries Limited, and UCB. Aaron S. Farberg has been an advisor for Amgen, Apogee, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Feldan, Galderma, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sun Pharma. Neal Bhatia is an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals. Mir Sohail Fazeli, Kimberly Hofer, and Otto Lam report employment with Evidinno Outcomes Research Inc. Victoria Barghout is CEO of Viver Health LLC, which receives funding from Bristol Myers Squibb, Novartis, Sun Pharma, and Taiho Pharmaceutical Co. Jacob Mathew reports employment with Sun Pharmaceutical Industries, Inc. Thomas J Ferro reports past employment with Sun Pharmaceutical Industries, Inc., and current employment with Data Loft, Inc.32:T710,Many biologic therapies are available for moderate-to-severe plaque psoriasis. A systematic literature review and network meta-analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)-23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate-to-severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid-term (28 weeks) follow-up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor-alpha (TNFα), IL-17, IL-12/IL-23, and other IL-23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate-to-severe plaque psoriasis.33:T760,ABSTRACTMany biologic therapies are available for moderate‐to‐severe plaque psoriasis. A systematic literature review and network meta‐analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)‐23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate‐to‐severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid‐term (28 weeks) follow‐up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor‐alpha (TNFα), IL‐17, IL‐12/IL‐23, and other IL‐23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate‐to‐severe plaque psoriasis.34:T4a2,This study aims to evaluate the clinical efficacy, recurrence rate, and drug retention rate of plaque psoriasis with different severity levels treated with Ixekizumab. A retrospective, multicenter, real-world study was conducted using the China Cathay database to analyze 354 Chinese patients with mild-to-moderate and severe psoriasis who received ixekizumab therapy. Psoriasis Area and Severity Index (PASI) 75/90/100 response rates, absolute PASI values, 3-year drug retention, and recurrence rates were assessed at 2, 4, 12, 24, and 52 weeks. The baseline PASI scores for the mild-to-moderate group (PASI <10) and severe group (PASI ≥ 10) were 5.6± 2.6 and 20 ± 11, respectively. Except for a difference in the proportion of male patients, there were no differences between the two groups in terms of age,duration of illness, hypertension, hyperlipidemia, cardiovascular diseases, gout and arthropathy. The mild-moderate group showed superior PASI75/90 responses at most timepoints and consistently higher PASI100 rates (all Ixekizumab demonstrates superior efficacy in mild-moderate versus severe psoriasis, suggesting greater benefit with early biologic intervention.35:Tbcc,Patients with psoriasis may require a switch to another therapy due to high treatment costs, primary effectiveness failure, biologic fatigue, or adverse effects associated with the initial biologic treatment; however, the availability of evidence for the effectiveness and safety of interclass biologic switching for the treatment of psoriasis is unknown. To investigate the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic. PubMed, Embase, and the Cochrane Library were searched from inception through January 25, 2025. The study included randomized clinical trials (RCTs) of patients with plaque psoriasis aged 18 years or older involving crossover or switching from 1 biologic agent to another initial biologic within the same or different drug class. Two researchers independently screened the records and abstracted data using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were pooled using random-effects models. The prespecified primary end point was psoriasis area and severity index (PASI) 90. Secondary end points included clinician- and patient-reported outcomes (PROMs) and safety. Clinical effectiveness was evaluated based on the PASI responses (PASI 75, 90, and 100) and the Investigator's and Physician's Global Assessments scores of 0 or 1 and body surface area of 1% or less. PROMs included the dermatology life quality index and psoriasis symptoms and signs diary. Safety concerns included adverse events (AEs), serious AEs, severe AEs, treatment-related AEs, and specific AEs. Twenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti-TNF-α agents to anti-interleukin (IL)-23p19, anti-IL-17A, or anti-IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively. This systematic review and meta-analysis found that interclass biologic switching was effective in a significant number of patients. With the introduction of biologics with diverse mechanisms of action, these options may become viable and potentially superior. However, further confirmatory data from larger patient cohorts and longer follow-up periods are required to obtain more conclusive results. Our results highlight the importance of vigilance for infections when switching biologics.36:Tef0,ImportancePatients with psoriasis may require a switch to another therapy due to high treatment costs, primary effectiveness failure, biologic fatigue, or adverse effects associated with the initial biologic treatment; however, the availability of evidence for the effectiveness and safety of interclass biologic switching for the treatment of psoriasis is unknown.ObjectiveTo investigate the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic.Data SourcesPubMed, Embase, and the Cochrane Library were searched from inception through January 25, 2025.Study SelectionThe study included randomized clinical trials (RCTs) of patients with plaque psoriasis aged 18 years or older involving crossover or switching from 1 biologic agent to another initial biologic within the same or different drug class.Data Extraction and SynthesisTwo researchers independently screened the records and abstracted data using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were pooled using random-effects models.Main Outcomes and MeasuresThe prespecified primary end point was psoriasis area and severity index (PASI) 90. Secondary end points included clinician- and patient-reported outcomes (PROMs) and safety. Clinical effectiveness was evaluated based on the PASI responses (PASI 75, 90, and 100) and the Investigator’s and Physician’s Global Assessments scores of 0 or 1 and body surface area of 1% or less. PROMs included the dermatology life quality index and psoriasis symptoms and signs diary. Safety concerns included adverse events (AEs), serious AEs, severe AEs, treatment-related AEs, and specific AEs.ResultsTwenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti−TNF-α agents to anti−interleukin (IL)-23p19, anti−IL-17A, or anti−IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively.Conclusions and RelevanceThis systematic review and meta-analysis found that interclass biologic switching was effective in a significant number of patients. With the introduction of biologics with diverse mechanisms of action, these options may become viable and potentially superior. However, further confirmatory data from larger patient cohorts and longer follow-up periods are required to obtain more conclusive results. Our results highlight the importance of vigilance for infections when switching biologics.37:T8fd,New, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease. To assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis. This phase 2b, randomized, double-blind, placebo-controlled, multiple-dose randomized clinical trial was conducted from August 11, 2021, to September 12, 2022, at 47 centers in the US and 8 in Canada. The study included a 12-week treatment period and a 4-week follow-up period. Key eligibility criteria for participants included age 18 to 70 years; a Psoriasis Area and Severity Index (PASI) score of 12 or greater; a Physician's Global Assessment score of 3 or greater; and a body surface area covered by plaque psoriasis of 10% or greater. Of 287 patients randomized, 259 (90.2%) received at least 1 dose of study treatment. Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients achieving 75% or greater improvement in PASI score (PASI 75) at week 12. Secondary efficacy end points included PASI 90 and 100 responses. Safety was also assessed. In total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters. This randomized clinical trial found that potent and selective inhibition of TYK2 with zasocitinib at oral doses of 5 mg or more once daily resulted in greater skin clearance than placebo over 12 weeks. ClinicalTrials.gov Identifier: NCT04999839.38:Tcbb,ImportanceNew, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease.ObjectiveTo assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis.Design, Setting, and ParticipantsThis phase 2b, randomized, double-blind, placebo-controlled, multiple-dose randomized clinical trial was conducted from August 11, 2021, to September 12, 2022, at 47 centers in the US and 8 in Canada. The study included a 12-week treatment period and a 4-week follow-up period. Key eligibility criteria for participants included age 18 to 70 years; a Psoriasis Area and Severity Index (PASI) score of 12 or greater; a Physician’s Global Assessment score of 3 or greater; and a body surface area covered by plaque psoriasis of 10% or greater. Of 287 patients randomized, 259 (90.2%) received at least 1 dose of study treatment.InterventionPatients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.Main Outcomes and MeasuresThe primary efficacy end point was the proportion of patients achieving 75% or greater improvement in PASI score (PASI 75) at week 12. Secondary efficacy end points included PASI 90 and 100 responses. Safety was also assessed.ResultsIn total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.Conclusions and RelevanceThis randomized clinical trial found that potent and selective inhibition of TYK2 with zasocitinib at oral doses of 5 mg or more once daily resulted in greater skin clearance than placebo over 12 weeks.Trial RegistrationClinicalTrials.gov Identifier: NCT0499983939:Tac5,Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies. To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis. The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis. In study part 2, reported herein, first and last patient visits were September 2019 and March 2022, respectively. In GUIDE part 1 (week [W]0-W28), patients received guselkumab, 100 mg, at W0, W4, W12, and W20. Those achieving a Psoriasis Area and Severity Index (PASI) of 0 at both W20 and W28 were termed super responders (SRes). In part 2 (W28-W68), SRes were randomized to guselkumab, 100 mg, every 8 weeks or every 16 weeks; non-SRes continued open-label guselkumab every 8 weeks. Primary objective was to demonstrate noninferiority (with a 10% margin) of guselkumab every 16 weeks vs every 8 weeks dosing among SRes for maintenance of disease control (PASI <3 at W68). Biomarker substudies assessed immunologic effects in skin and blood. Overall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks/every 16 weeks; n = 148/n = 149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (P = .001), with 91.9% (137/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)-cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and β defensin (BD)-2 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified. Psoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease activity. ClinicalTrials.gov Identifier: NCT03818035.3a:Te2a,ImportancePsoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies.ObjectiveTo evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis.Design, Setting, and ParticipantsThe GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis. In study part 2, reported herein, first and last patient visits were September 2019 and March 2022, respectively.InterventionsIn GUIDE part 1 (week [W]0-W28), patients received guselkumab, 100 mg, at W0, W4, W12, and W20. Those achieving a Psoriasis Area and Severity Index (PASI) of 0 at both W20 and W28 were termed super responders (SRes). In part 2 (W28-W68), SRes were randomized to guselkumab, 100 mg, every 8 weeks or every 16 weeks; non-SRes continued open-label guselkumab every 8 weeks.Main Outcomes and MeasuresPrimary objective was to demonstrate noninferiority (with a 10% margin) of guselkumab every 16 weeks vs every 8 weeks dosing among SRes for maintenance of disease control (PASI &lt;3 at W68). Biomarker substudies assessed immunologic effects in skin and blood.ResultsOverall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks/every 16 weeks; n = 148/n = 149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (P = .001), with 91.9% (137/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)–cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and β defensin (BD)–2 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified.Conclusions and RelevancePsoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease activity.Trial RegistrationClinicalTrials.gov Identifier: NCT038180353b:T44d,Overall, 104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the PF-07038124 group and 36.1 [13.9] years in the vehicle group) and 34 with plaque psoriasis (20 men [58.8%]; mean [SD] ages, 51.8 [12.3] years in the PF-07038124 group and 51.2 [10.8] years in the vehicle group). Baseline characteristics were generally balanced. At week 6, the PF-07038124 groups showed significantly greater improvements compared with vehicle groups in EASI (least-squares mean CFB, -74.9% vs -35.5%; difference, -39.4% [90% CI, -58.8% to -20.1%]; P < .001) and PASI scores (CFB, -4.8 vs 0.1; difference, -4.9 [90% CI, -7.0 to -2.8]; P < .001). The number of patients with treatment-emergent adverse events was comparable between treatment groups in patients with AD (PF-07038124, 9 [25.0%]; vehicle, 9 [26.5%]) and plaque psoriasis (PF-07038124, 3 [17.6%]; vehicle, 6 [35.3%]). There were no application site reactions with PF-07038124 treatment.3c:T958,Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions. To assess the efficacy and safety of the topical phosphodiesterase 4 inhibitor PF-07038124 in patients with AD and plaque psoriasis. This phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across 4 countries. Eligible patients (aged 18-70 years) had mild to moderate AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area). Data were analyzed until December 15, 2021. Patients were randomized (1:1) to PF-07038124, 0.01%, topical ointment or vehicle once daily for 6 weeks. The primary end point was the percent change from baseline (CFB) in the Eczema Area and Severity Index (EASI) total score among patients with AD and in the Psoriasis Area and Severity Index (PASI) score among patients with plaque psoriasis at week 6. Safety measures included treatment-emergent adverse events, including application site reactions. Overall, 104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the PF-07038124 group and 36.1 [13.9] years in the vehicle group) and 34 with plaque psoriasis (20 men [58.8%]; mean [SD] ages, 51.8 [12.3] years in the PF-07038124 group and 51.2 [10.8] years in the vehicle group). Baseline characteristics were generally balanced. At week 6, the PF-07038124 groups showed significantly greater improvements compared with vehicle groups in EASI (least-squares mean CFB, -74.9% vs -35.5%; difference, -39.4% [90% CI, -58.8% to -20.1%]; P < .001) and PASI scores (CFB, -4.8 vs 0.1; difference, -4.9 [90% CI, -7.0 to -2.8]; P < .001). The number of patients with treatment-emergent adverse events was comparable between treatment groups in patients with AD (PF-07038124, 9 [25.0%]; vehicle, 9 [26.5%]) and plaque psoriasis (PF-07038124, 3 [17.6%]; vehicle, 6 [35.3%]). There were no application site reactions with PF-07038124 treatment. Topical PF-07038124 was well tolerated and demonstrated superior efficacy compared with vehicle in patients with mild to moderate AD and plaque psoriasis. ClinicalTrials.gov Identifier: NCT04664153.3d:Tccc,ImportanceAtopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions.ObjectiveTo assess the efficacy and safety of the topical phosphodiesterase 4 inhibitor PF-07038124 in patients with AD and plaque psoriasis.Design, Setting, and ParticipantsThis phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across 4 countries. Eligible patients (aged 18-70 years) had mild to moderate AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area). Data were analyzed until December 15, 2021.InterventionsPatients were randomized (1:1) to PF-07038124, 0.01%, topical ointment or vehicle once daily for 6 weeks.Main Outcomes and MeasuresThe primary end point was the percent change from baseline (CFB) in the Eczema Area and Severity Index (EASI) total score among patients with AD and in the Psoriasis Area and Severity Index (PASI) score among patients with plaque psoriasis at week 6. Safety measures included treatment-emergent adverse events, including application site reactions.ResultsOverall, 104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the PF-07038124 group and 36.1 [13.9] years in the vehicle group) and 34 with plaque psoriasis (20 men [58.8%]; mean [SD] ages, 51.8 [12.3] years in the PF-07038124 group and 51.2 [10.8] years in the vehicle group). Baseline characteristics were generally balanced. At week 6, the PF-07038124 groups showed significantly greater improvements compared with vehicle groups in EASI (least-squares mean CFB, −74.9% vs −35.5%; difference, −39.4% [90% CI, −58.8% to −20.1%]; P &lt; .001) and PASI scores (CFB, −4.8 vs 0.1; difference, −4.9 [90% CI, −7.0 to −2.8]; P &lt; .001). The number of patients with treatment-emergent adverse events was comparable between treatment groups in patients with AD (PF-07038124, 9 [25.0%]; vehicle, 9 [26.5%]) and plaque psoriasis (PF-07038124, 3 [17.6%]; vehicle, 6 [35.3%]). There were no application site reactions with PF-07038124 treatment.Conclusions and RelevanceTopical PF-07038124 was well tolerated and demonstrated superior efficacy compared with vehicle in patients with mild to moderate AD and plaque psoriasis.Trial RegistrationClinicalTrials.gov Identifier: NCT046641533e:T7c8,Orismilast is a high-potency phosphodiesterase 4 (PDE4) inhibitor with enhanced selectivity for the PDE4B and PDE4D subtypes. The objective of this phase 2a trial was to examine the efficacy and safety of orismilast for psoriasis using a first-generation immediate-release (IR) formulation. The objective of the subsequent phase 1 trial was to test new formulations designed to minimize the gastrointestinal (GI)-related adverse events (AEs) observed with the first-generation IR formulation. We examined the following: (1) pharmacokinetic (PK) properties of orismilast modified release (MR) and IR, (2) food effects on PK properties of orismilast MR or IR, (3) safety of orismilast MR compared to placebo. In a phase 2a prospective, randomized, double-blind, placebo-controlled trial, patients with moderate-to-severe psoriasis were randomized to receive 30 mg oral orismilast IR or placebo over 16 weeks. The single-site phase 1 trial consisted of three parts: (1) participants received a single 30 mg dose of orismilast MR and IR (open-label), (2) participants received 30 mg orismilast MR or IR under either fasting condition, following a high-fat meal or low-fat meal (open-label) and (3) participants received up to 60 mg orismilast MR twice-daily or a placebo for 17 days (double-blind). In the phase 2a trial, treatment with orismilast IR significantly improved the mean Psoriasis Area Severity Index score at week 16 compared to placebo. The phase 1 trial revealed comparable PK properties of the orismilast MR and IR formulations, with participants in the orismilast MR group experiencing fewer GI-related AEs than those receiving orismilast IR (16.7% vs. 33.3%). Orismilast IR displayed higher efficacy compared to placebo in patients with moderate-to-severe psoriasis at week 16. Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.3f:T972,AbstractBackgroundOrismilast is a high‐potency phosphodiesterase 4 (PDE4) inhibitor with enhanced selectivity for the PDE4B and PDE4D subtypes.ObjectivesThe objective of this phase 2a trial was to examine the efficacy and safety of orismilast for psoriasis using a first‐generation immediate‐release (IR) formulation. The objective of the subsequent phase 1 trial was to test new formulations designed to minimize the gastrointestinal (GI)‐related adverse events (AEs) observed with the first‐generation IR formulation. We examined the following: (1) pharmacokinetic (PK) properties of orismilast modified release (MR) and IR, (2) food effects on PK properties of orismilast MR or IR, (3) safety of orismilast MR compared to placebo.MethodsIn a phase 2a prospective, randomized, double‐blind, placebo‐controlled trial, patients with moderate‐to‐severe psoriasis were randomized to receive 30 mg oral orismilast IR or placebo over 16 weeks. The single‐site phase 1 trial consisted of three parts: (1) participants received a single 30 mg dose of orismilast MR and IR (open‐label), (2) participants received 30 mg orismilast MR or IR under either fasting condition, following a high‐fat meal or low‐fat meal (open‐label) and (3) participants received up to 60 mg orismilast MR twice‐daily or a placebo for 17 days (double‐blind).ResultsIn the phase 2a trial, treatment with orismilast IR significantly improved the mean Psoriasis Area Severity Index score at week 16 compared to placebo. The phase 1 trial revealed comparable PK properties of the orismilast MR and IR formulations, with participants in the orismilast MR group experiencing fewer GI‐related AEs than those receiving orismilast IR (16.7% vs. 33.3%).ConclusionOrismilast IR displayed higher efficacy compared to placebo in patients with moderate‐to‐severe psoriasis at week 16. Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Plaque Psoriasis: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Plaque Psoriasis (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Plaque%20Psoriasis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Plaque Psoriasis\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Plaque%20Psoriasis\"}]}}"}}]],["$","$L2f",null,{"title":"Plaque Psoriasis: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Plaque Psoriasis with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0593","pmid":"42658202","title":"A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-08-27T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0593","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-03T06:20:03.656Z","updated_at":"2026-09-03T06:20:03.656Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"brand","value":"Ilumetri","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"sample_size","value":"n=72","value_numeric":72},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"study_design","value":"Delphi Consensus Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"Down-titration recommendations are based solely on expert opinion; tildrakizumab-specific dose-reduction outcome data are lacking.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"Only 35 of 48 statements (73%) reached the predefined ≥75% consensus threshold, meaning several clinically important dosing scenarios—including all-patient initiation at 100 mg, prior IL-17 failure, and cardiometabolic syndrome—did not achieve consensus.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"The study included only European dermatologists; applicability to other regions or healthcare systems is uncertain.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0593","tag_type":"warning","value":"This is an expert consensus (Delphi) study funded by Almirall (tildrakizumab manufacturer); all steering group members received honoraria, which may introduce bias despite stated safeguards.","value_numeric":null}],"summaries":{"what_studied":"A modified Delphi study surveyed 72 experienced European dermatologists across 9 countries to build pan-European consensus on when to initiate, up-titrate, or down-titrate tildrakizumab 100 mg vs. 200 mg in adults with moderate-to-severe plaque psoriasis. Consensus was predefined as ≥75% agreement across 48 statements.","key_result":"Consensus was reached on 35 of 48 statements (73%). Strong agreement supported: 100 mg for weight <90 kg + BMI <25, moderate disease (PASI >5–<16, DLQI >5–<10), or biologic-naïve patients; 200 mg for weight ≥90 kg and/or BMI ≥25 (both 97%), severe disease (PASI ≥16, 89%), prior IL-23p19 inhibitor failure (78%), or ≥2 biologic failures (76%). Up-titration to 200 mg was supported for partial response (PASI ≥2) after 24–28 weeks (93%) or itch NRS >4 (93%); down-titration to 100 mg was supported after ≥1 year of PASI 100 remission on 200 mg (93%).","limitations":"- Convenience sampling across 9 countries limits generalizability beyond represented European healthcare settings.\n- Biologic failure was not precisely defined, and severity thresholds for high-impact areas were left undefined.\n- Consensus recommendations are not validated against clinical outcomes and require prospective confirmation.","practice_takeaway":"Start tildrakizumab at 100 mg in biologic-naïve patients with moderate disease and weight <90 kg/BMI <25; use 200 mg upfront in heavier, sicker, or biologic-experienced patients. Consider up-titration to 200 mg if PASI ≥2 persists at 24–28 weeks, and down-titration to 100 mg after ≥1 year of complete remission."}},{"doi":"10.1093/ced/llag301","pmid":"42462170","title":"Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma","journal_title":"Clinical and Experimental Dermatology","journal_issn":"0307-6938","published_at":"2026-07-16T00:00:00.000Z","url":"https://doi.org/10.1093/ced/llag301","source_score":5,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-25T13:57:53.676Z","updated_at":"2026-07-25T13:57:53.676Z","tags":[{"paper_doi":"10.1093/ced/llag301","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"condition","value":"Follicular Lymphoma","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"generic","value":"CD19 CAR-T cells","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1093/ced/llag301","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"warning","value":"Single case report — the 'practice_changing' impact flag reflects the mechanistic novelty and duration of remission, not established clinical guidance; findings require prospective validation.","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"warning","value":"The paper was published July 16, 2026, and today's date is July 25, 2026 — this is very recent literature with no post-publication peer commentary available yet.","value_numeric":null},{"paper_doi":"10.1093/ced/llag301","tag_type":"warning","value":"The remission could be partially attributable to lymphodepletion conditioning chemotherapy rather than CAR-T therapy itself, which the authors acknowledge but cannot fully exclude.","value_numeric":null}],"summaries":{"what_studied":"A 60-year-old woman with a 49-year history of severe, treatment-refractory plaque psoriasis was observed after receiving autologous CD19-directed CAR-T cell therapy for follicular lymphoma, to assess its incidental effect on psoriasis.","key_result":"Psoriasis resolved within 4 weeks of CD19 CAR-T therapy and remained in complete remission for over 4.5 years without any psoriasis-directed treatment.","limitations":"Single case report limits generalizability; remission may be confounded by lymphoma-directed conditioning or other treatment effects; CAR-T therapy carries significant toxicity risk that precludes routine use for psoriasis alone.","practice_takeaway":"This case suggests that deep B-cell depletion via CD19 CAR-T therapy may induce long-term psoriasis remission, challenging the T cell-only model of psoriasis pathogenesis. Clinicians should be aware of this emerging signal, though CAR-T therapy for psoriasis alone is not yet established or recommended."}},{"doi":"10.1093/bjd/ljag264","pmid":"42397072","title":"Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-07-03T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag264","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-12T13:19:43.419Z","updated_at":"2026-07-12T13:19:43.419Z","tags":[{"paper_doi":"10.1093/bjd/ljag264","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"brand","value":"Sotyktu","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"generic","value":"deucravacitinib","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"generic","value":"icotrokinra","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"modality","value":"IL-23 Receptor Antagonist","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"modality","value":"TYK2 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"sample_size","value":"n=1505","value_numeric":1505},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"warning","value":"Crossover design after Week 16/24 means Week 52 efficacy data for the placebo and deucravacitinib arms reflect icotrokinra use, not continued comparator exposure — long-term head-to-head comparative data are unavailable.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"warning","value":"Icotrokinra is described as a 'targeted oral peptide' — its regulatory approval status as of the paper's publication date is not stated in the abstract; clinicians should verify current approval status before prescribing.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag264","tag_type":"warning","value":"The brand name for icotrokinra is not confirmed in the source text; no brand tag was applied for icotrokinra. The Sotyktu brand tag applies only to deucravacitinib.","value_numeric":null}],"summaries":{"what_studied":"Two phase 3 RCTs (ICONIC-ADVANCE 1 & 2; N=1,505 adults) evaluated the 52-week durability of once-daily oral icotrokinra 200 mg versus placebo and deucravacitinib 6 mg once daily in adults with moderate-to-severe plaque psoriasis (BSA ≥10%, PASI ≥12, IGA ≥3).","key_result":"At Weeks 24–52, ~70–75% of icotrokinra-randomised participants achieved IGA 0/1 or PASI 90, and ~50% achieved IGA 0 or PASI 100; of those with clear/almost clear skin at Week 16, ~85–90% maintained response at Week 52. Participants switching from placebo (at Week 16) or deucravacitinib (at Week 24) to icotrokinra reached comparable response rates by Week 52. No safety signals were identified through Week 52.","limitations":"- No direct Week 52 head-to-head comparison with deucravacitinib (crossover design limits long-term comparative efficacy conclusions).\n- Open-label extension phase after crossovers may introduce performance bias.\n- Findings may not generalise beyond adults with moderate-to-severe disease meeting strict entry criteria.","practice_takeaway":"Oral icotrokinra (IL-23R blocker) delivers durable skin clearance through one year, with a safety profile comparable to placebo at 16 weeks and better than deucravacitinib at 24 weeks — making it a compelling all-oral systemic option for moderate-to-severe plaque psoriasis. Patients who do not respond adequately to deucravacitinib can transition to icotrokinra and reach similar clearance rates within 52 weeks."}},{"doi":"10.1007/s13555-026-01839-2","pmid":"42393457","title":"Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01839-2","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-08T13:26:30.683Z","updated_at":"2026-07-08T13:26:30.683Z","tags":[{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"generic","value":"icotrokinra","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"modality","value":"IL-23 Receptor Blocker","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"study_design","value":"Matching-Adjusted Indirect Comparison (MAIC)","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"Level of evidence assigned as 3 (indirect comparison using individual patient data); this reflects MAIC methodology, which sits below RCT-level evidence.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"No proprietary brand name for icotrokinra was confirmed in the source text; it is listed generically only.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"Sample size for the MAIC was not explicitly reported in the abstract or results; the tag was omitted accordingly.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"The MAIC was sponsored by Johnson & Johnson (risankizumab manufacturer), which may introduce bias favoring risankizumab.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01839-2","tag_type":"warning","value":"The paper metadata and full text appear to contain content from a separate conference poster (ICONIC-ADVANCE durability data) embedded within the PDF, which is distinct from the MAIC study being summarized; only the MAIC abstract content was used for extraction.","value_numeric":null}],"summaries":{"what_studied":"This matching-adjusted indirect comparison (MAIC) evaluated the relative efficacy of risankizumab (injectable IL-23 inhibitor) versus icotrokinra (oral IL-23 receptor blocker) in adults with moderate-to-severe plaque psoriasis through week 52, using individual patient data from phase 3 risankizumab trials and published summary data from icotrokinra phase 3 trials (ICONIC-ADVANCE 1 & 2).","key_result":"At week 16, placebo-adjusted response rates significantly favored risankizumab over icotrokinra across all endpoints: PASI 75 (80.6% vs 61.7%; RD +18.9%, 95% CI 11.5–26.4; P<0.001), PASI 90 (71.4% vs 49.9%; RD +21.5%, 95% CI 15.6–27.4; P<0.001), PASI 100 (42.3% vs 29.4%; RD +13.0%, 95% CI 7.9–18.0; P<0.001), IGA 0/1 (77.8% vs 58.4%; RD +19.4%; P<0.001), and IGA 0 (41.6% vs 33.9%; RD +7.7%; P<0.05); differences were consistent through week 52.","limitations":"- No head-to-head trial exists; MAIC relies on cross-trial assumptions that may not fully account for unmeasured confounders.\n- Unanchored analyses at weeks 24 and 52 lack a shared placebo arm, increasing potential for residual bias.\n- The study was funded by the risankizumab manufacturer (AbbVie/J&J sponsorship context), introducing industry conflict of interest.","practice_takeaway":"When choosing between an injectable IL-23 inhibitor (risankizumab) and the new oral IL-23 receptor blocker (icotrokinra) for moderate-to-severe plaque psoriasis, this indirect comparison suggests risankizumab achieves meaningfully higher skin clearance rates at all time points through one year. Clinicians should weigh this efficacy gap against patient preference for an oral therapy, bearing in mind the inherent limitations of cross-trial comparisons."}},{"doi":"10.1007/s13555-026-01797-9","pmid":"42262460","title":"Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-06-09T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01797-9","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-17T13:29:45.016Z","updated_at":"2026-06-17T13:29:45.016Z","tags":[{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"modality","value":"IL-17A Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"sample_size","value":"n=769","value_numeric":769},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"study_design","value":"Multicenter Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"warning","value":"Several authors disclosed financial relationships with Novartis (secukinumab's manufacturer) and other biologic makers; no external funding was reported, but conflicts of interest are extensive.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"warning","value":"Survivor bias is a major confounder: the study enrolled only patients who completed ≥4 years of continuous secukinumab, systematically excluding non-responders and those with early AEs, which substantially inflates the reported long-term effectiveness figures.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"warning","value":"The cohort shrinks markedly at later time points (n=231 at year 6, n=101 at year 7), limiting the generalizability of the longest follow-up data.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01797-9","tag_type":"warning","value":"The higher PASI 100 rates in PsA patients is an exploratory finding from univariate subgroup analysis without multiplicity correction — caution is warranted in clinical interpretation.","value_numeric":null}],"summaries":{"what_studied":"This multicenter retrospective study evaluated the real-world long-term effectiveness and safety of secukinumab (300 mg SC every 4 weeks) in 769 adults with moderate-to-severe plaque psoriasis treated continuously for at least 4 years across 15 Italian dermatology units (2017–2025), with follow-up up to 7 years.","key_result":"PASI 90 rose from 36.0% at week 16 to 90.0% at year 6; PASI 100 rose from 27.4% at week 16 to 80.2% at year 7. Absolute PASI ≤2 reached 95.0% at year 7. Patients with concomitant PsA had significantly higher PASI 100 rates at years 5 (77.9% vs. 69.8%) and 6 (85.7% vs. 71.4%; p ≤ 0.05). Serious AEs led to permanent discontinuation in only 5 patients (3 de novo malignancies, 1 pulmonary embolism, 1 eosinophilic pneumonia).","limitations":"- **Survivor bias**: only patients on continuous treatment ≥4 years were included; early discontinuers (for inefficacy, AEs, or preference) are excluded, inflating long-term response rates.\n- **Retrospective, as-observed analysis**: missing data could not be recovered, and progressively smaller cohorts at later time points (n=769 at year 4 down to n=101 at year 7) limit interpretation.\n- **No formal drug survival analysis or multivariate adjustment**: confounders cannot be excluded, and subgroup findings should be considered exploratory.","practice_takeaway":"In patients who tolerate and respond to secukinumab, skin clearance rates continue to improve over years — not plateau — suggesting strong long-term durability for those who stay on therapy. Cardiometabolic comorbidities and difficult-to-treat areas did not significantly reduce response rates, supporting secukinumab as a durable option regardless of these factors."}},{"doi":"10.2340/actadv.v106.adv-2026-0461","pmid":"42257527","title":"Prior Specific Biologic Use as a Potential Risk Factor for Administration-related Reactions to Ixekizumab after Excipient Modification: A Single-centre Retrospective Study","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-06-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0461","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:43.016Z","updated_at":"2026-06-10T14:24:43.016Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Erythrodermic Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Generalized Pustular Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"modality","value":"IL-17A Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"sample_size","value":"n=23","value_numeric":23},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"warning","value":"All authors have disclosed financial relationships with multiple pharmaceutical companies, including Eli Lilly (ixekizumab manufacturer), which may introduce bias.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"warning","value":"ARR definition relied on clinical records from a single centre, with potential for ascertainment variability.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"warning","value":"Very small sample size (n=23) produces highly imprecise odds ratios (e.g., 95% CI 1.41–192.00); findings should be considered hypothesis-generating only.","value_numeric":null}],"summaries":{"what_studied":"This single-centre retrospective study examined risk factors for administration-related reactions (ARRs) to the modified (citrate-free) ixekizumab formulation in 23 psoriasis patients treated between January 2023 and December 2025.","key_result":"7 of 23 patients (30.4%) developed ARRs; 6 of those 7 had switched from secukinumab. Multivariate logistic regression showed prior secukinumab use was significantly associated with ARRs (OR 16.40, 95% CI 1.41–192.00, p=0.03). All ARRs were grade 1; 4 women discontinued ixekizumab due to intolerable reactions.","limitations":"Very small sample size (n=23) from a single centre limits generalisability; wide confidence intervals reflect imprecision; no mechanistic data to confirm causal pathway between prior secukinumab use and ARRs.","practice_takeaway":"When switching psoriasis patients from secukinumab to ixekizumab, counsel them about a higher likelihood of injection-site reactions, even with the newer citrate-free formulation. Monitor closely after the first dose and have a contingency plan if reactions are intolerable."}},{"doi":"10.1001/jamadermatol.2026.1753","pmid":"42139049","title":"Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1753","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-18T13:25:20.466Z","updated_at":"2026-05-18T13:25:20.466Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"brand","value":"Zepbound","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"condition","value":"Overweight","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"generic","value":"tirzepatide","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"modality","value":"GIP/GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"modality","value":"IL-17A Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"sample_size","value":"n=274","value_numeric":274},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"warning","value":"Level of evidence tagged as '2' rather than '1' due to open-label (non-blinded) design despite randomization.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"warning","value":"Open-label design (not blinded) is a notable methodological limitation that the authors acknowledge; objective endpoints like PASI may be less prone to bias, but weight-related outcomes could be influenced.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"warning","value":"The trial is ongoing (52-week endpoint not yet reported); results here reflect the week 36 primary endpoint only.","value_numeric":null}],"summaries":{"what_studied":"Phase 3b RCT (n=274) evaluating ixekizumab + tirzepatide vs. ixekizumab alone (both with diet and exercise) over 52 weeks in adults with moderate-to-severe plaque psoriasis and overweight/obesity (mean BMI 39.2) at 72 US sites; primary endpoint assessed at week 36.","key_result":"At week 36, 27.1% on combination therapy vs. 5.8% on ixekizumab alone simultaneously achieved PASI 100 and ≥10% weight loss (RD 21.2%; 95% CI 12.8%–29.7%; P<.001). PASI 100 alone: 40.6% vs. 29.0% (P=.04). ≥10% weight reduction: 69.2% vs. 9.1% (RD 60.0%). GI adverse events were more common in the combination arm.","limitations":"Open-label design may introduce assessment bias. The trial was conducted exclusively at US sites, limiting generalizability. Week 52 data were not yet available at the time of analysis.","practice_takeaway":"For patients with moderate-to-severe psoriasis and obesity, adding tirzepatide to ixekizumab produces substantially greater skin clearance and weight loss than ixekizumab alone, with no new safety signals. Clinicians should counsel patients on higher rates of GI side effects with the combination."}},{"doi":"10.1007/s13555-026-01774-2","pmid":"42105056","title":"Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-05-09T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01774-2","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-14T13:22:44.638Z","updated_at":"2026-05-14T13:22:44.638Z","tags":[{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"brand","value":"Ilumya","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"condition","value":"Scalp Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"sample_size","value":"n=171","value_numeric":171},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"study_design","value":"Randomized Controlled Trial (Subgroup Analysis)","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"warning","value":"Brand name 'Ilumya' used; tildrakizumab is also marketed as 'Ilumetri' in some regions — clinicians should verify local brand names.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"warning","value":"Sample size tag reflects the modified intention-to-treat (mITT) population (n=171); the full ITT population was n=231. The subgroup Ns are smaller and vary by analysis.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01774-2","tag_type":"warning","value":"The study used only the 100 mg dose of tildrakizumab; some guidelines recommend 200 mg for patients with obesity, so generalizability to higher-dose decisions is limited.","value_numeric":null}],"summaries":{"what_studied":"This subgroup analysis of a Phase 3b randomized, double-blind, placebo-controlled trial examined whether obesity (BMI ≥30 vs. <30 kg/m²) affects the efficacy and safety of tildrakizumab 100 mg for moderate-to-severe scalp psoriasis in adults over 52 weeks (NCT03897088, conducted in the USA and Australia).","key_result":"At Week 16, tildrakizumab significantly outperformed placebo regardless of obesity status: IGA mod 2011 (scalp) response was achieved by 48.8% (obese) vs. 10.0% (placebo) and 50.0% (non-obese) vs. 4.8% (placebo); PSSI 90 response was 62.8% (obese) vs. 10.0% (placebo) and 58.7% (non-obese) vs. 0.0% (placebo). No statistically significant difference in efficacy or safety was found between patients with vs. without obesity through Week 52.","limitations":"- Subgroup analysis was not prospectively powered to detect differences between obesity groups, limiting conclusions about effect modification.\n- Relatively small subgroup sizes (obese on tildrakizumab: n=43; non-obese: n=46) reduce precision.\n- Only tildrakizumab 100 mg was studied; results may not extend to the 200 mg dose used in heavier patients in other trials.","practice_takeaway":"Tildrakizumab 100 mg appears effective and safe for scalp psoriasis in patients with obesity, with response rates comparable to non-obese patients through 52 weeks. Clinicians need not expect meaningfully reduced efficacy in obese patients treated with this agent for scalp disease."}},{"doi":"10.1007/s13555-025-01625-6","pmid":"41501565","title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-01-08T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-025-01625-6","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-10","doi":"10.1007/s13555-025-01625-6","days":"7","issn":"2193-8210","rank":"8","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1007/s13555-025-01625-6","title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.","journal":"Dermatology and therapy","methods":"","results":"Of 6982 records screened, 37 studies (45 publications) were analyzed. Tildrakizumab-treated patients experienced 78-87% improvement from baseline to 36-52 weeks across mean absolute PASI (12.81 [95% confidence interval 11.69, 13.92] to 1.62 [1.03, 2.20]), %BSA (16.21% [13.72%, 18.70%] to 3.27% [1.26%, 5.28%]), PGA (3.18 [2.89, 3.47] to 0.70 [0.08, 1.33]), and DLQI (14.59 [12.32, 16.87] to 1.83 [0.84, 2.82]), with low rates of AEs, SAEs, TRAEs, and WDAEs. Benefits and safety of tildrakizumab were similar to guselkumab and risankizumab.","abstract":"$30","keywords":["Effectiveness","Psoriasis","Quality of life","Real-world evidence","Safety","Systematic review","Tildrakizumab"],"pubmed_id":"41501565","conclusions":"Tildrakizumab demonstrated effectiveness, with reduction from moderate-to-severe to mild disease and improved DLQI scores, without notable safety concerns, for up to 1 year in this real-world meta-analysis. Although real-world data must be interpreted cautiously because of heterogeneity and potential bias, these findings align with randomized trial results, further supporting the use of tildrakizumab in clinical practice.","publication_date":"2026-01-08T00:00:00"},"crossref":{"DOI":"10.1007/s13555-025-01625-6","URL":"https://doi.org/10.1007/s13555-025-01625-6","ISSN":["2193-8210","2190-9172"],"link":[{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/article/10.1007/s13555-025-01625-6","content-type":"text/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis"],"author":[{"given":"Scott","family":"Gottlieb","sequence":"first","affiliation":[]},{"given":"Aaron S.","family":"Farberg","sequence":"additional","affiliation":[]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[]},{"given":"Kimberly","family":"Hofer","sequence":"additional","affiliation":[]},{"given":"Otto","family":"Lam","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Barghout","sequence":"additional","affiliation":[]},{"given":"Jacob","family":"Mathew","sequence":"additional","affiliation":[]},{"given":"Thomas J.","family":"Ferro","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100013671","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,7]]},"member":"297","prefix":"10.1007","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T16:11:01Z","timestamp":1767802261000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T20:04:27Z","timestamp":1767816267791,"date-parts":[[2026,1,7]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000,"date-parts":[[2026,1,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://link.springer.com/10.1007/s13555-025-01625-6"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"ArticleHistory","label":"Article History"},"label":"Received","order":1,"value":"31 October 2025"},{"name":"accepted","group":{"name":"ArticleHistory","label":"Article History"},"label":"Accepted","order":2,"value":"5 December 2025"},{"name":"first_online","group":{"name":"ArticleHistory","label":"Article History"},"label":"First Online","order":3,"value":"7 January 2026"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"},"order":1},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"},"order":2,"value":"$31"},{"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"},"order":3,"value":"This article is based on previously conducted studies and does not include any new studies with human participants or animals performed by any of the authors."}],"deposited":{"date-time":"2026-01-07T17:01:40Z","timestamp":1767805300000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"published":{"date-parts":[[2026,1,7]]},"publisher":"Springer Science and Business Media LLC","reference":[{"DOI":null,"key":"1625_CR1","year":"2013","issue":"9","author":"N Weigle","volume":"87","first-page":"626","unstructured":"Weigle N, McBane S. Psoriasis. Am Fam Phys. 2013;87(9):626–33.","article-title":null,"journal-title":"Am Fam Phys","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2008.02.039","key":"1625_CR2","year":"2008","issue":"5","author":"A Menter","volume":"58","first-page":"826","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature05663","key":"1625_CR3","year":"2007","issue":"7130","author":"MA Lowes","volume":"445","first-page":"866","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.","article-title":null,"journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.11.057","key":"1625_CR4","year":"2019","issue":"4","author":"A Menter","volume":"80","first-page":"1029","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR5","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ILUMYA® (tildrakizumab-asmn) injection, for subcutaneous use. Full Prescribing Information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(17)31279-5","key":"1625_CR6","year":"2017","issue":"10091","author":"K Reich","volume":"390","first-page":"276","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.","article-title":null,"journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-022-00793-z","key":"1625_CR7","year":"2022","issue":"10","author":"D Thaçi","volume":"12","first-page":"2325","unstructured":"Thaçi D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325–41.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"European Medicines Agency. Ilumetri. 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri. Accessed 30 September 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1080/09546634.2017.1422591","key":"1625_CR9","year":"2018","issue":"6","author":"J Bilal","volume":"29","first-page":"569","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569–78.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1155/2019/2546161","key":"1625_CR10","year":"2019","issue":null,"author":"F Bai","volume":"2019","first-page":"2546161","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, Tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","article-title":null,"journal-title":"J Immunol Res","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.4029","key":"1625_CR11","year":"2020","issue":"3","author":"AW Armstrong","volume":"156","first-page":"258","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.","article-title":null,"journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-022-02065-w","key":"1625_CR12","year":"2022","issue":"5","author":"CL Leonardi","volume":"39","first-page":"2256","unstructured":"Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256–69.","article-title":null,"journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for systematic reviews of interventions version 6.4 (updated 2023 August): Oxford: The Cochrane Collaboration; 2020. www.training.cochrane.org/handbook. Accessed 30 Sept 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1136/bmj.n71","key":"1625_CR14","year":"2021","issue":null,"author":"MJ Page","volume":"372","first-page":"n71","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","article-title":null,"journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2014. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 Sept 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Joanna Briggs Institute. Critical appraisal tools: checklist for analytical cross-sectional studies 2022. https://jbi.global/critical-appraisal-tools. Accessed 30 Sept 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/1741-7015-12-93","key":"1625_CR17","year":"2014","issue":null,"author":"S Cope","volume":"12","first-page":"93","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93.","article-title":null,"journal-title":"BMC Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR18","year":"2023","issue":null,"author":"JJ Deeks","volume":null,"first-page":null,"unstructured":"Deeks JJ, Higgins JPT. Chapter 10 Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. UK: Cochrane Statistical Methods Group; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s00266-022-02977-6","key":"1625_CR19","year":"2023","issue":"suppl 1","author":"Y Chen","volume":"47","first-page":"83","unstructured":"Chen Y, Chen D, Wang Y, Han Y. Using Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Aesth Plast Surg. 2023;47(suppl 1):83–4.","article-title":null,"journal-title":"Aesth Plast Surg","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15228","key":"1625_CR20","year":"2022","issue":"2","author":"A Narcisi","volume":"35","first-page":"e15228","unstructured":"Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-022-00722-y","key":"1625_CR21","year":"2022","issue":"6","author":"T Torres","volume":"23","first-page":"891","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904.","article-title":null,"journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR22","year":"2023","issue":null,"author":"BB Bris","volume":null,"first-page":null,"unstructured":"Bris BB, De la Fuente H, del Mar Llamas Velasco M, et al. Polymorphism study as biomarkers of response to tildrakizumab. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR23","year":"2023","issue":null,"author":"A Downs","volume":null,"first-page":null,"unstructured":"Downs A, Barea A, Cammish G, et al. Real-world effectiveness of tildrakizumab in a UK cohort: a drug survival analysis. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2022.06.141","key":"1625_CR24","year":"2022","issue":"suppl 3","author":"N Kahen","volume":"87","first-page":"AB27","unstructured":"Kahen N, Ali Y, West DP. Cerebrovascular accident events associated with IL-23 inhibition: pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) from the RADAR (Research on Adverse Drug Events And Reports) program. J Am Acad Dermatol. 2022;87(suppl 3):AB27.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR25","year":"2023","issue":null,"author":"L Burzi","volume":null,"first-page":null,"unstructured":"Burzi L, Mastorino L, Dapavo P, Ribero S, Quaglino P. Psoriasis of the scalp, genital area, and palmoplantar psoriasis: efficacy of modern biologics drugs in difficult-to-treat areas. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-022-00800-3","key":"1625_CR26","year":"2022","issue":"10","author":"G Becher","volume":"12","first-page":"2343","unstructured":"Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343–54.","article-title":null,"journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19468","key":"1625_CR27","year":"2023","issue":"12","author":"S Berenguer-Ruiz","volume":"37","first-page":"2517","unstructured":"Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37(12):2517–25.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.3390/ph16040526","key":"1625_CR28","year":"2023","issue":"4","author":"E Campione","volume":"16","first-page":"526","unstructured":"Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16(4):526.","article-title":null,"journal-title":"Pharmaceuticals (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.947","key":"1625_CR29","year":"2023","issue":"3","author":"S Khattri","volume":"89","first-page":"AB237","unstructured":"Khattri S, Gooderham M, Reich A, et al. The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naive and -experienced patients: a post-hoc analysis of patients receiving treatment according to US labels. J Am Acad Dermatol. 2023;89(3):AB237.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18376","key":"1625_CR30","year":"2022","issue":"11","author":"A Pinter","volume":"36","first-page":"2087","unstructured":"Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087–100.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2133531","key":"1625_CR31","year":"2023","issue":"1","author":"CDB Elgaard","volume":"34","first-page":"2133531","unstructured":"Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR32","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Grabowski K, Narbutt J, Lesiak A, Skibińska M, Noweta M, editors. Real-world effectiveness of interleukin-23 inhibitors in plaque psoriasis in patients from a tertiary dermatology centre. Seville: European Academy of Dermatology and Venerology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1038/s41598-022-18790-9","key":"1625_CR33","year":"2022","issue":"1","author":"T Graier","volume":"12","first-page":"15078","unstructured":"Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12(1):15078.","article-title":null,"journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR34","year":"2023","issue":null,"author":"A Merchán","volume":"30","first-page":"A74","unstructured":"Merchán A, Lucía SC, Raquel FM, et al. Comparison of the effectiveness between interleukin-23 inhibitors for treatment of psoriasis in a third level hospital. Eur J Clin Pharm. 2023;30:A74.","article-title":null,"journal-title":"Eur J Clin Pharm","doi-asserted-by":null},{"DOI":"10.1111/dth.15793","key":"1625_CR35","year":"2022","issue":"11","author":"F Ricceri","volume":"35","first-page":"e15793","unstructured":"Ricceri F, Chiricozzi A, Peris K, Prignano F. Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: a multicentric retrospective study. Dermatol Ther. 2022;35(11):e15793.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2081655","key":"1625_CR36","year":"2022","issue":"6","author":"M Megna","volume":"33","first-page":"2813","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–20.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.14979","key":"1625_CR37","year":"2022","issue":"3","author":"A Ruggiero","volume":"47","first-page":"561","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–7.","article-title":null,"journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"TREMFYA® (guselkumab) injection, for subcutaneous or intravenous use. Full Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR39","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous or intravenous use. Full Prescribing Information. North Chicago, IL: AbbVie Inc.; 2025.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR40","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Rodica O, Ana-Maria C, Maria-Magdalena C, editors. IL23 inhibitors in psoriasis-case series. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR41","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Alarcon SS, Ramos FJM, Diaz JM, et al, editors. Tildrakizumab in the treatment of moderate to severe plaque psoriasis: 52 weeks of real-world experience in the Valencian Community. Milan: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.36849/jdd.6830","key":"1625_CR42","year":"2023","issue":"8","author":"J Bagel","volume":"22","first-page":"766","unstructured":"Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. J Drugs Dermatol. 2023;22(8):766–72.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR43","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Baratta S, Mortato E, Viola R, Poli MA, De Caro AP, Loconsole F, editors. Real-life experience with tildrakizumab in our clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR44","year":"2023","issue":"suppl 4","author":"G Becher","volume":"188","first-page":"ljad113. 35","unstructured":"Becher G, Stephen K, McInnes A, et al. Clinical priorities when treating psoriasis: insights from a real-world data study of tildrakizumab. Br J Dermatol. 2023;188(suppl 4):ljad113. 35.","article-title":null,"journal-title":"Br J Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.jaad.2022.06.826","key":"1625_CR45","year":"2022","issue":"3","author":"N Bhatia","volume":"87","first-page":"AB199","unstructured":"Bhatia N, Heim J, Torres M, Beute P, Rozzo SJ, Vasquez JG. Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: week 28 interim analysis of a phase 4 study. J Am Acad Dermatol. 2022;87(3):AB199.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jval.2023.03.2445","key":"1625_CR46","year":"2023","issue":"6","author":"N Bhatia","volume":"26","first-page":"S57","unstructured":"Bhatia N, Vasquez JG, Schenkel B, Rozzo SJ, Heim J. Real-world effectiveness and safety in a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis. Value Health. 2023;26(6):S57.","article-title":null,"journal-title":"Value Health","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.865","key":"1625_CR47","year":"2023","issue":"3","author":"N Bhatia","volume":"89","first-page":"AB216","unstructured":"Bhatia N, Vasquez JG, Schenkel B, Rozzo SJ, Heim J. Real-world effectiveness of tildrakizumab in a phase 4 study in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB216.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2023.2200872","key":"1625_CR48","year":"2023","issue":"1","author":"N Bhatia","volume":"34","first-page":"2200872","unstructured":"Bhatia N, Heim J, Schenkel B, Vasquez JG. Quality of life and patient-reported symptoms in a phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis. J Dermatolog Treat. 2023;34(1):2200872.","article-title":null,"journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.36849/jdd.7471","key":"1625_CR49","year":"2023","issue":"8","author":"J Heim","volume":"22","first-page":"754","unstructured":"Heim J, Vasquez JG, Schenkel B, Bhatia N. Real-world effectiveness and safety of tildrakizumab in patients with moderate-to-severe psoriasis: week 28 interim analysis of a phase 4 study. J Drugs Dermatol. 2023;22(8):754–60.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.344","key":"1625_CR50","year":"2023","issue":"3","author":"JG Vasquez","volume":"89","first-page":"AB85","unstructured":"Vasquez JG, Bhatia N, Schenkel B, Rozzo SJ, Heim J. Safety of tildrakizumab in a phase 4 real-world study in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB85.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.07.819","key":"1625_CR51","year":"2023","issue":"3","author":"J Heim","volume":"89","first-page":"AB204","unstructured":"Heim J, Vasquez JG, Rozzo SJ, Schenkel B, Bhatia N. Patients’ quality of life in a phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB204.","article-title":null,"journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.36849/JDD.6828","key":"1625_CR52","year":"2022","issue":"8","author":"A Brunasso","volume":"21","first-page":"914","unstructured":"Brunasso A. Nail psoriasis improvement during tildrakizumab therapy: a real-life experience. J Drugs Dermatol. 2022;21(8):914–6.","article-title":null,"journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR53","year":"2021","issue":null,"author":"M Burlando","volume":"10","first-page":"2021-6-8","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2021-6–8.","article-title":null,"journal-title":"Drugs Context","doi-asserted-by":null},{"DOI":null,"key":"1625_CR54","year":"2022","issue":"18","author":"M Burlando","volume":"26","first-page":"6772","unstructured":"Burlando M, Maul JT, Salvi I, et al. Psoriasis patients’ characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci. 2022;26(18):6772–6.","article-title":null,"journal-title":"Eur Rev Med Pharmacol Sci","doi-asserted-by":null},{"DOI":null,"key":"1625_CR55","year":"2022","issue":"6","author":"G Caldarola","volume":"35","first-page":"e15488","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":null},{"DOI":null,"key":"1625_CR56","year":"2023","issue":null,"author":"S Lambiase","volume":null,"first-page":null,"unstructured":"Lambiase S, Shumak RG, Lanna C, et al. A real life clinical experience of tildrakizumab in patients affected by psoriasis and metabolic comorbidities. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR57","year":"2022","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Daudén E, et al. Tildrakizumab improves symptoms of pruritus, pain, and scaling in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Milan: European Academy of Dermatology and Venereology Congress; 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR58","year":"2023","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Daudén E, et al. Super responders to tildrakizumab treatment in moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR59","year":"2023","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Daudén E, et al. Tildrakizumab demonstrates high efficacy and a favourable safety profile in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Singapore: World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR60","year":"2023","issue":null,"author":"A Costanzo","volume":null,"first-page":null,"unstructured":"Costanzo A, Cuccia A, Dauden E, et al. Tildrakizumab demonstrates high efficacy regardless of baseline characteristics in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.19229","key":"1625_CR61","year":"2023","issue":"10","author":"A Costanzo","volume":"37","first-page":"2004","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004–15.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.5826/dpc.1304a215","key":"1625_CR62","year":"2023","issue":"4","author":"EV Di Brizzi","volume":"13","first-page":"e2023215","unstructured":"Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept. 2023;13(4):e2023215.","article-title":null,"journal-title":"Dermatol Pract Concept","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR63","year":"2023","issue":null,"author":"K Drerup","volume":null,"first-page":null,"unstructured":"Drerup K, Seemann C, Gerdes S, Mrowiet U. Tildrakizumab in psoriasis: extended real world data from a prospective cohort study (KTC). Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1159/000519924","key":"1625_CR64","year":"2022","issue":"4","author":"KA Drerup","volume":"238","first-page":"615","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615–9.","article-title":null,"journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR65","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Escalas J, Palos CM, Ramos AL, editors. Tildrakizumab experience in real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR66","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Fornons-Servent R, Ferrer AL, Vilarrasa E, et al editors. Real-world evidence of effectiveness and safety of tildrakizumab in patients with moderate to severe psoriasis from 8 hospitals. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.3390/jcm11092631","key":"1625_CR67","year":"2022","issue":"9","author":"M Galluzzo","volume":"11","first-page":"2631","unstructured":"Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631.","article-title":null,"journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.65","key":"1625_CR68","year":"2023","issue":"1","author":"A Gambardella","volume":"2","first-page":"52","unstructured":"Gambardella A, Licata G, De Rosa A, Calabrese G, Alfano R, Argenziano G. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. JEADV Clin Pract. 2023;2(1):52–8.","article-title":null,"journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15818","key":"1625_CR69","year":"2022","issue":"11","author":"L Mastorino","volume":"35","first-page":"e15818","unstructured":"Mastorino L, Cariti C, Susca S, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35(11):e15818.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR70","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Maul J-T, Steinmann S, Rosset N, et al editors. Management of moderate-to-severe psoriasis with tildrakizumab: first real-world-evidence results in a Swiss patient cohort from the SDNTT registry. Geneva: Schweizerische Gesellschaft für Dermatologie und Venerologie; 2021.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.18594","key":"1625_CR71","year":"2023","issue":"1","author":"A Narcisi","volume":"37","first-page":"93","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study—IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR72","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Rodriguez Fernandez-Freire L, Ortiz J, Hernandez JC, Morillo M, Barabash R, Conejo-Mir J, editors. Tildrakizumab: efficacy and safety in mid-term (52 weeks) on real clinical practice in 32 patients with moderate-to-severe psoriasis. Singapore: 25th World Congress of Dermatology; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/dth.15941","key":"1625_CR73","year":"2022","issue":"12","author":"A Ruggiero","volume":"35","first-page":"e15941","unstructured":"Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.","article-title":null,"journal-title":"Dermatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S402183","key":"1625_CR74","year":"2023","issue":null,"author":"A Ruggiero","volume":"16","first-page":"529","unstructured":"Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529–36.","article-title":null,"journal-title":"Clin Cosmet Investig Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm11175098","key":"1625_CR75","year":"2022","issue":"17","author":"R Ruiz-Villaverde","volume":"11","first-page":"5098","unstructured":"Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-Gutierrez M. Tildrakizumab: efficacy, safety and survival in mid-term (52 weeks) in three tertiary hospitals in Andalucia (Spain). J Clin Med. 2022;11(17):5098.","article-title":null,"journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR76","year":"2023","issue":null,"author":"M Augustin","volume":null,"first-page":null,"unstructured":"Augustin M, Sommer R, Reguiai Z, et al. Real-world effectiveness, quality of life, and treatment satisfaction with tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR77","year":"2023","issue":null,"author":"U Mrowietz","volume":null,"first-page":null,"unstructured":"Mrowietz U, Sommer R, Reguiai Z, et al. Real-world safety of tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR78","year":"2023","issue":null,"author":"R Sommer","volume":null,"first-page":null,"unstructured":"Sommer R, Augustin M, Reguiai Z, et al. Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data of the phase IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR79","year":"2022","issue":null,"author":"A Tsianakas","volume":null,"first-page":null,"unstructured":"Tsianakas A, Ostendorf R, Diemert S, Asadullah K. Tildrakizumab improves quality of life in patients with moderate-to-severe chronic plaque psoriasis in a real-life setting. Milan: European Academy of Dermatology and Venereology Congress; 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jdv.18572","key":"1625_CR80","year":"2023","issue":"1","author":"A Tsianakas","volume":"37","first-page":"85","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85–92.","article-title":null,"journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"1625_CR81","year":"2023","issue":null,"author":"A Tsianakas","volume":null,"first-page":null,"unstructured":"Tsianakas A, Kirsch A, Petri M. Sustained efficacy and safety of tildrakizumab over 2 years in patients with moderate to severe plaque psoriasis in routine clinical practice: interim results in week 100 from the non-interventional, prospective, multicenter study TILOT. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"1625_CR82","year":"2023","issue":null,"author":"A Tsianakas","volume":null,"first-page":null,"unstructured":"Tsianakas A, Kirsch A, Schwichtenberg U. Tildrakizumab improves signs and symptoms in patients with moderate to severe plaque psoriasis in a realworld setting: a holistic approach. Berlin: European Academy of Dermatology and Venereology Congress; 2023.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1177/24755303221077211","key":"1625_CR83","year":"2022","issue":"2","author":"NW Wei","volume":"7","first-page":"55","unstructured":"Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55–9.","article-title":null,"journal-title":"J Psoriasis Psoriatic Arthritis","doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1007/springer_crossmark_policy","alternative-id":["1625"],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"original-title":[],"container-title":["Dermatology and Therapy"],"reference-count":83,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,7]]},"references-count":83,"short-container-title":["Dermatol Ther (Heidelb)"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1007/s13555-025-01625-6","is_oa":true,"title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-07","best_oa_location":{"url":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","pmh_id":null,"url_for_pdf":"https://link.springer.com/content/pdf/10.1007/s13555-025-01625-6.pdf","url_for_landing_page":"https://doi.org/10.1007/s13555-025-01625-6"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Comparative results versus guselkumab and risankizumab are qualitative without effect sizes.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Design classification reflects a meta-analysis of real-world observational studies with expected heterogeneity.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Safety is summarized as 'low rates' without absolute numbers in the abstract.","value_numeric":null},{"paper_doi":"10.1007/s13555-025-01625-6","tag_type":"warning","value":"Total patient N is not reported in the abstract; only the number of studies is given.","value_numeric":null}],"summaries":{"what_studied":"A systematic review and meta-analysis of real-world studies evaluated tildrakizumab for adults with chronic moderate-to-severe plaque psoriasis, including comparisons with guselkumab and risankizumab. Outcomes were PASI, PGA, %BSA, DLQI, and safety at 12–16, 24–28, and 36–52 weeks across 37 studies (45 publications).","key_result":"From baseline to 36–52 weeks, mean PASI fell from 12.81 (95% CI 11.69–13.92) to 1.62 (1.03–2.20), %BSA from 16.21% (13.72–18.70) to 3.27% (1.26–5.28), PGA from 3.18 (2.89–3.47) to 0.70 (0.08–1.33), and DLQI from 14.59 (12.32–16.87) to 1.83 (0.84–2.82), reflecting 78–87% improvement, with low AE, SAE, TRAE, and WDAE rates. Effectiveness and safety were similar to guselkumab and risankizumab.","limitations":"Heterogeneity and potential bias across real-world observational studies; English-language restriction; follow-up limited to about 1 year.","practice_takeaway":"In routine care, tildrakizumab yields large, sustained improvements in disease severity and quality of life over up to 1 year with few safety concerns, and its performance appears comparable to guselkumab and risankizumab."}},{"doi":"10.1111/ijd.70092","pmid":"41115146","title":"Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis","journal_title":"International Journal of Dermatology","journal_issn":"0011-9059","published_at":"2025-10-20T00:00:00.000Z","url":"https://doi.org/10.1111/ijd.70092","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-25","doi":"10.1111/ijd.70092","days":"14","issn":"0011-9059","rank":"9","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/ijd.70092","title":"Efficacy of Biologics for the Treatment of Moderate-To-Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta-Analysis.","journal":"International journal of dermatology","methods":"","results":"","abstract":"$32","keywords":["Asian population","SOC","biologics","meta‐analysis","psoriasis","skin of color","systematic review","tildrakizumab"],"pubmed_id":"41115146","conclusions":"","publication_date":"2025-10-20T00:00:00"},"crossref":{"DOI":"10.1111/ijd.70092","URL":"https://doi.org/10.1111/ijd.70092","ISSN":["0011-9059","1365-4632"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.70092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis"],"author":[{"given":"Akihiko","family":"Asahina","sequence":"first","affiliation":[{"name":"The Jikei University School of Medicine Tokyo Japan"}]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Robyn","family":"Kendall","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Gopika","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. Princeton New Jersey USA"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. Princeton New Jersey USA"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Beijing China"}]}],"funder":[{"id":[{"id":"10.13039/501100013671","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,10,20]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-20T15:39:01Z","timestamp":1760974741000,"date-parts":[[2025,10,20]]},"indexed":{"date-time":"2025-10-20T16:38:54Z","timestamp":1760978334520,"date-parts":[[2025,10,20]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000,"date-parts":[[2025,10,20]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/ijd.70092"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-15"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-23"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-20"}],"deposited":{"date-time":"2025-10-20T15:39:04Z","timestamp":1760974744000,"date-parts":[[2025,10,20]]},"issn-type":[{"type":"print","value":"0011-9059"},{"type":"electronic","value":"1365-4632"}],"published":{"date-parts":[[2025,10,20]]},"publisher":"Wiley","reference":[{"DOI":"10.1038/nature05663","key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3386","key":"e_1_2_10_3_1","year":"2020","issue":"3","author":"Reid C.","volume":"100","first-page":null,"unstructured":null,"article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","journal-title":"Acta Dermato‐Venereologica","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2015.02.003","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.11.055","key":"e_1_2_10_5_1","year":"2011","issue":"1","author":"American Academy of Dermatology Work Group","volume":"65","first-page":"137","unstructured":null,"article-title":"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 6. Guidelines of Care for the Treatment of Psoriasis and Psoriatic Arthritis: Case‐Based Presentations and Evidence‐Based Conclusions","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12325-022-02065-w","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.4029","key":"e_1_2_10_7_1","year":"2020","issue":"3","author":"Armstrong A. W.","volume":"156","first-page":"258","unstructured":null,"article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta‐Analysis","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0220868","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17448","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-022-00843-6","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.1432","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.l4898","key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/0272989X12458724","key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.6475","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1467-9868.00353","key":"e_1_2_10_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“HUMIRA (Adalimumab) Prescribing Information ”(2021) http://www.rxabbvie.com/pdf/humira.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“CIMZIA (Cetrolizumab Pegol) Prescribing Information ”(2024) https://www.cimziahcp.com/full‐prescribing‐info.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Remicade (Infliximab) Prescribing Information ”(2021) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/REMICADE‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Bimzelx (Bimekizumab) Prescribing Information ”(2024) https://www.bimzelxhcp.com/prescribing‐information.pdf?_gl=1%2Athjj0v%2A_ga%2ANDUxMjQ1OTQ3LjE3Mjk2Njc5MjA.%2A_ga_CKX2D73W9W%2AMTczMTQwMjY0Ni41MS4xLjE3MzE0MDQ3MTguMC4wLjA.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“SILIQ (Brodalumab) Prescribing Information ”(2024) https://www.bauschhealth.com/Portals/25/Pdf/PI/Siliq‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“TALTZ (Ixekizumab) Prescribing Information ”(2024) http://uspl.lilly.com/taltz/taltz.html?s=pi.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Cosentyx (Secukinumab) Prescribing Information ”(2024) https://www.novartis.com/us‐en/sites/novartis_us/files/cosentyx.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Tremfya (Guselkumab) Prescribing Information ”(2024) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/TREMFYA‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Skyrizi (Risankizumab) Prescribing Information ”(2024) https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“ILUMYA (Tildrakizumab) Prescribing Information ”(2022) https://www.ilumya.com/Sun_Pharma_ILUMYA_US_Prescribing_Information_.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Stelara (Ustekinumab) Prescribing Information ”(2019) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/STELARA‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/j.1346-8138.2009.00748.x","key":"e_1_2_10_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13746","key":"e_1_2_10_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00520-0","key":"e_1_2_10_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Clinicaltrials.gov “NCT03051217. A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis ”https://clinicaltrials.gov/study/NCT03051217.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jdermsci.2010.04.014","key":"e_1_2_10_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_32_1","year":"2012","issue":"11","author":"Yang H. Z.","volume":"125","first-page":"1845","unstructured":null,"article-title":"Infliximab Monotherapy for Chinese Patients With Moderate to Severe Plaque Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Trial","journal-title":"Chinese Medical Journal","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Clinicaltrials.gov “NCT01177800. A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque‐Type Psoriasis ”(2025) https://clinicaltrials.gov/study/NCT01177800.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-022-00883-y","key":"e_1_2_10_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2015.10.009","key":"e_1_2_10_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15733","key":"e_1_2_10_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.13927","key":"e_1_2_10_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/JD9.0000000000000244","key":"e_1_2_10_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.12668","key":"e_1_2_10_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.13900","key":"e_1_2_10_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000001163","key":"e_1_2_10_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14504","key":"e_1_2_10_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14941","key":"e_1_2_10_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15789","key":"e_1_2_10_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000002873","key":"e_1_2_10_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2011.05.005","key":"e_1_2_10_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1346-8138.2011.01347.x","key":"e_1_2_10_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_48_1","year":"2013","issue":"2","author":"Zhu X.","volume":"12","first-page":"166","unstructured":null,"article-title":"Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque‐Type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(17)31279-5","key":"e_1_2_10_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19866","key":"e_1_2_10_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_51_1","year":"2021","issue":null,"author":"Burlando M.","volume":"10","first-page":null,"unstructured":null,"article-title":"Treatment of Moderate‐To‐Severe Plaque Psoriasis With Tildrakizumab in the Real‐Life Setting","journal-title":"Drugs in Context","doi-asserted-by":null},{"DOI":"10.1111/jdv.19229","key":"e_1_2_10_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15763","key":"e_1_2_10_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.10.017","key":"e_1_2_10_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.042","key":"e_1_2_10_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.041","key":"e_1_2_10_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)31713-6","key":"e_1_2_10_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_58_1","year":"2023","issue":"7","author":"Sbidian E.","volume":"7","first-page":null,"unstructured":null,"article-title":"Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta‐Analysis","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.1007/s13555-025-01423-0","key":"e_1_2_10_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.xjidi.2024.100261","key":"e_1_2_10_60_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/ijd.70092"],"article-number":"ijd.70092","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["International Journal of Dermatology"],"reference-count":59,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,20]]},"references-count":59,"short-container-title":["Int J Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/ijd.70092","is_oa":false,"title":"Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis","updated":"2025-10-21T16:47:13+00:00","published_date":"2025-10-20","best_oa_location":null}},"created_at":"2025-10-27T13:37:43.000Z","updated_at":"2025-11-05T07:41:18.588Z","tags":[{"paper_doi":"10.1111/ijd.70092","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Comparative effect sizes and credible intervals are not provided; “comparable” at Week 28 is qualitative in the abstract.","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Safety results were within scope but not summarized in the abstract.","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Total number of participants across trials is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and Bayesian network meta-analysis of 19 randomized trials from China, Japan, Korea, and Taiwan comparing tildrakizumab with 10 other biologics in adult Asian patients with moderate-to-severe plaque psoriasis over 12–28 weeks, using PASI 75/90/100 and PGA 0/1.","key_result":"At Week 12, tildrakizumab showed lower efficacy than other biologics. From Weeks 12 to 28, PASI responses with tildrakizumab increased from 60.77%→81.84% (PASI 75), 38.54%→71.23% (PASI 90), and 6.97%→22.64% (PASI 100); by Week 28, efficacy was comparable to TNFα, IL-17, IL-12/23, and other IL-23 inhibitors.","practice_takeaway":"For Asian adults starting tildrakizumab, expect slower early clearance by 12 weeks but marked gains by 28 weeks, reaching parity with other biologics. Its sustained improvement and low dosing frequency support it as an effective option for moderate-to-severe plaque psoriasis."}},{"doi":"10.1080/09546634.2025.2562299","pmid":"41031544","title":"Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients","journal_title":"Journal of Dermatological Treatment","journal_issn":"0954-6634","published_at":"2025-10-01T00:00:00.000Z","url":"https://doi.org/10.1080/09546634.2025.2562299","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-05","doi":"10.1080/09546634.2025.2562299","days":"7","issn":"0954-6634","rank":"9","field":"Clinical Medicine","score":"4","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1080/09546634.2025.2562299","title":"Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients.","journal":"The Journal of dermatological treatment","methods":"","results":"The baseline PASI scores for the mild-to-moderate group (PASI <10) and severe group (PASI ≥ 10) were 5.6± 2.6 and 20 ± 11, respectively. Except for a difference in the proportion of male patients, there were no differences between the two groups in terms of age,duration of illness, hypertension, hyperlipidemia, cardiovascular diseases, gout and arthropathy. The mild-moderate group showed superior PASI75/90 responses at most timepoints and consistently higher PASI100 rates (all ","abstract":"$34","keywords":["PASI","Psoriasis","drug retention rate","interleukin-17A","ixekizumab","recurrence rate"],"pubmed_id":"41031544","conclusions":"","publication_date":"2025-10-01T00:00:00"},"crossref":{"DOI":"10.1080/09546634.2025.2562299","URL":"https://doi.org/10.1080/09546634.2025.2562299","ISSN":["0954-6634","1471-1753"],"link":[{"URL":"https://www.tandfonline.com/doi/pdf/10.1080/09546634.2025.2562299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients"],"author":[{"given":"Zhuhui","family":"Qiao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shenzhen Hospital, Beijing University of Chinese Medicine (Longgang)"}]},{"given":"Bao","family":"Chai","sequence":"additional","affiliation":[{"name":"Affiliated Nanshan Hospital of Shenzhen University"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xijing Hospital, The Fourth Military Medical University"}]},{"given":"Hong-zhong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Dermatology, Dermatology Hospital of Southern Medical University"}]},{"given":"Fuqiu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Norman Bethune Hospital, Jilin University"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Hong Kong-Shenzhen Hospital"}]},{"given":"Lantuya","family":"Wu","sequence":"additional","affiliation":[{"name":"Shenzhen People’s Hospital"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Shantou University Medical College"}]},{"given":"Lin","family":"Dang","sequence":"additional","affiliation":[{"name":"Shenzhen People’s Hospital"}]},{"given":"XiaoJing","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, People’s Hospital of Xinjiang Uygur Autonomous Region"}]},{"given":"Xiaoming","family":"Liu","sequence":"additional","affiliation":[{"name":"Affiliated Nanshan Hospital of Shenzhen University"},{"name":"Department of Dermatology, The University of Hong Kong-Shenzhen Hospital"}]}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Foundation Committee","award":["2022A1515111066"]},{"name":"The Sanming Project of Medicine in Shenzhen","award":["SZSM202103014"]},{"name":"The High Level-Hospital Program, Health Commission of Guangdong Province, China","award":["HKUSZH201906001"]}],"issued":{"date-parts":[[2025,10]]},"member":"301","prefix":"10.1080","source":"Crossref","volume":"36","created":{"date-time":"2025-10-01T10:29:11Z","timestamp":1759314551000,"date-parts":[[2025,10,1]]},"indexed":{"date-time":"2025-10-02T00:42:54Z","timestamp":1759365774203,"date-parts":[[2025,10,2]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2562299"}},"subtitle":[],"assertion":[{"name":"peerreview_statement","label":"Peer Review Statement","order":1,"value":"The publishing and review policy for this title is described in its Aims & Scope."},{"URL":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijdt20","name":"aims_and_scope_url","label":"Aim & Scope","order":2,"value":"http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ijdt20"},{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-28"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-10"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-01"}],"deposited":{"date-time":"2025-10-01T10:29:13Z","timestamp":1759314553000,"date-parts":[[2025,10,1]]},"issn-type":[{"type":"print","value":"0954-6634"},{"type":"electronic","value":"1471-1753"}],"published":{"date-parts":[[2025,10]]},"publisher":"Informa UK Limited","reference":[{"DOI":"10.1038/jid.2012.194","key":"e_1_3_7_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/1744666x.2019.1559730","key":"e_1_3_7_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.36849/jdd.8160","key":"e_1_3_7_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17695","key":"e_1_3_7_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2021.11.018","key":"e_1_3_7_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/s0140-6736(21)00184-7","key":"e_1_3_7_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-025-01423-0","key":"e_1_3_7_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2025.03.014","key":"e_1_3_7_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.0288","key":"e_1_3_7_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_7_11_1","year":"2019","issue":"10","author":"Chinese Society of Dermatology and Venereology, Psoriasis Committee, Chinese Medical Association","volume":"52","first-page":"667","unstructured":"Chinese Society of Dermatology and Venereology, Psoriasis Committee, Chinese Medical Association. Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2018 Complete Edition). Chin J Dermatol. 2019;52(10):667–710.","article-title":"Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2018 Complete Edition)","journal-title":"Chin J Dermatol","doi-asserted-by":null},{"DOI":"10.2217/imt-2023-0013","key":"e_1_3_7_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.intimp.2024.113474","key":"e_1_3_7_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-024-02976-w","key":"e_1_3_7_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-024-03030-5","key":"e_1_3_7_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16915","key":"e_1_3_7_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.18453","key":"e_1_3_7_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/art.42758","key":"e_1_3_7_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-025-01435-w","key":"e_1_3_7_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-025-01436-9","key":"e_1_3_7_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20256","key":"e_1_3_7_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10067-023-06859-3","key":"e_1_3_7_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.farma.2024.04.012","key":"e_1_3_7_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40265-025-02192-y","key":"e_1_3_7_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2022.2909","key":"e_1_3_7_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1468-3083.2010.03705.x","key":"e_1_3_7_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s41927-025-00498-8","key":"e_1_3_7_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.1677","key":"e_1_3_7_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s42003-025-07960-w","key":"e_1_3_7_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ebiom.2024.104985","key":"e_1_3_7_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s11845-025-03969-6","key":"e_1_3_7_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"update-policy":"https://doi.org/10.1080/tandf_crossmark_01","alternative-id":["10.1080/09546634.2025.2562299"],"article-number":"2562299","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2025,12,31]]},"reference-count":30,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10]]},"references-count":30,"short-container-title":["Journal of Dermatological Treatment"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1080/09546634.2025.2562299","is_oa":true,"title":"Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: a multicenter retrospective analysis of 354 patients","updated":"2025-10-02T02:48:41+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://doi.org/10.1080/09546634.2025.2562299","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1080/09546634.2025.2562299"}}},"created_at":"2025-10-11T07:13:56.506Z","updated_at":"2025-10-12T07:02:35.737Z","tags":[{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"sample_size","value":"n=354","value_numeric":354},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"warning","value":"Abstract details appear truncated; numeric PASI response rates and statistical measures were not provided.","value_numeric":null},{"paper_doi":"10.1080/09546634.2025.2562299","tag_type":"warning","value":"Design classified as a retrospective cohort based on the description; exact methodology was not fully detailed.","value_numeric":null}],"summaries":{"what_studied":"Retrospective, multicenter real‑world analysis of 354 Chinese patients with plaque psoriasis (mild–moderate PASI <10 vs severe PASI ≥10) treated with ixekizumab, assessing PASI75/90/100, absolute PASI at 2, 4, 12, 24, and 52 weeks, plus 3‑year drug retention and recurrence.","key_result":"Baseline PASI averaged 5.6±2.6 in the mild–moderate group and 20±11 in the severe group; the mild–moderate group achieved higher PASI75/90 at most time points and consistently higher PASI100 rates versus the severe group. Groups were otherwise similar in age, disease duration, and comorbidities, except for a difference in male proportion.","limitations":"Retrospective design using a single-country database may limit causal inference and generalizability. Sex distribution differed between severity groups, introducing potential confounding. Numeric response rates, drug retention, and recurrence results were not reported in the provided text.","practice_takeaway":"Expect stronger PASI responses to ixekizumab in milder plaque psoriasis than in severe disease; set patient expectations accordingly and consider earlier biologic use when appropriate."}},{"doi":"10.1001/jamadermatol.2025.2714","pmid":"40768223","title":"Biopharmaceutical Switching in Psoriasis Treatment","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-08-06T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.2714","source_score":82,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-19","doi":"10.1001/jamadermatol.2025.2714","days":"30","issn":"2168-6068","rank":"6","field":"Clinical Medicine","score":"82","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.2714","title":"Biopharmaceutical Switching in Psoriasis Treatment: A Systematic Review and Meta-Analysis.","journal":"JAMA dermatology","methods":"","results":"Twenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti-TNF-α agents to anti-interleukin (IL)-23p19, anti-IL-17A, or anti-IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively.","abstract":"$35","keywords":[],"pubmed_id":"40768223","conclusions":"","publication_date":"2025-08-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.2714","URL":"https://doi.org/10.1001/jamadermatol.2025.2714","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2837167/jamadermatology_zhang_2025_oi_250038_1760475172.18406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1029","type":"journal-article","issue":"10","score":1,"title":["Biopharmaceutical Switching in Psoriasis Treatment"],"author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Qingyun","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Yaqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Naixuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Juntang","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]}],"issued":{"date-parts":[[2025,10,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-08-06T15:00:39Z","timestamp":1754492439000,"date-parts":[[2025,8,6]]},"indexed":{"date-time":"2025-10-16T00:52:14Z","timestamp":1760575934867,"date-parts":[[2025,10,16]]},"subject":[],"abstract":"$36","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2837167"}},"subtitle":["A Systematic Review and Meta-Analysis"],"deposited":{"date-time":"2025-10-15T15:02:25Z","timestamp":1760540545000,"date-parts":[[2025,10,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,10,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1038/nrd1607","key":"doi250038r1","year":"2005","issue":"1","author":"Gottlieb","volume":"4","first-page":"19","unstructured":null,"article-title":"Psoriasis: emerging therapeutic strategies.","journal-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher"},{"DOI":"10.1080/17512433.2020.1767590","key":"doi250038r2","year":"2020","issue":"5","author":"Tsai","volume":"13","first-page":"493","unstructured":null,"article-title":"Switching biologics in psoriasis - practical guidance and evidence to support.","journal-title":"Expert Rev Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2013.826341","key":"doi250038r3","year":"2014","issue":"1","author":"Levin","volume":"25","first-page":"78","unstructured":null,"article-title":"Biologic fatigue in psoriasis.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2230.2001.00829.x","key":"doi250038r4","year":"2001","issue":"4","author":"van de Kerkhof","volume":"26","first-page":"356","unstructured":null,"article-title":"Therapeutic strategies: rotational therapy and combinations.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2024.103530","key":"doi250038r5","year":"2024","issue":"4","author":"Sun","volume":"23","first-page":null,"unstructured":null,"article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence.","journal-title":"Autoimmun Rev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.11.057","key":"doi250038r6","year":"2019","issue":"4","author":"Menter","volume":"80","first-page":"1029","unstructured":null,"article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-023-40222-5","key":"doi250038r7","year":"2023","issue":"1","author":"de Oliveira Ascef","volume":"13","first-page":"13699","unstructured":null,"article-title":"Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2017-211937","key":"doi250038r8","year":"2018","issue":"2","author":"Kay","volume":"77","first-page":"165","unstructured":null,"article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.02.1221","key":"doi250038r9","year":"2016","issue":"3","author":"Yamauchi","volume":"75","first-page":"612","unstructured":null,"article-title":"Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.11.022","key":"doi250038r10","year":"2021","issue":"2","author":"Blauvelt","volume":"85","first-page":"360","unstructured":null,"article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"doi250038r11","year":"1994","issue":"3","author":"Finlay","volume":"19","first-page":"210","unstructured":null,"article-title":"Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2015.1114567","key":"doi250038r12","year":"2016","issue":"4","author":"Mathias","volume":"27","first-page":"322","unstructured":null,"article-title":"Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljac021","key":"doi250038r13","year":"2023","issue":"1","author":"Thaçi","volume":"188","first-page":"22","unstructured":null,"article-title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2102388","key":"doi250038r14","year":"2021","issue":"2","author":"Warren","volume":"385","first-page":"130","unstructured":null,"article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.04.063","key":"doi250038r15","year":"2023","issue":"3","author":"Strober","volume":"89","first-page":"486","unstructured":null,"article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.15750","key":"doi250038r16","year":"2018","issue":"1","author":"Langley","volume":"178","first-page":"114","unstructured":null,"article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljac089","key":"doi250038r17","year":"2023","issue":"3","author":"Kokolakis","volume":"188","first-page":"330","unstructured":null,"article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17454","key":"doi250038r18","year":"2019","issue":"5","author":"Reich","volume":"180","first-page":"1039","unstructured":null,"article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.11.004","key":"doi250038r19","year":"2022","issue":"4","author":"Blauvelt","volume":"86","first-page":"827","unstructured":null,"article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.05.032","key":"doi250038r20","year":"2018","issue":"5","author":"Leonardi","volume":"79","first-page":"824","unstructured":null,"article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15921","key":"doi250038r21","year":"2020","issue":"2","author":"Lebwohl","volume":"34","first-page":"301","unstructured":null,"article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(19)30952-3","key":"doi250038r22","year":"2019","issue":"10198","author":"Reich","volume":"394","first-page":"576","unstructured":null,"article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19866","key":"doi250038r23","year":"2021","issue":"2","author":"Thaci","volume":"185","first-page":"323","unstructured":null,"article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250038r25","year":"1998","issue":"1","author":"Noble","volume":"58","first-page":"163","unstructured":null,"article-title":"Diagnosis and management of common tinea infections.","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1080/17476348.2021.1988569","key":"doi250038r26","year":"2021","issue":"12","author":"Wang","volume":"15","first-page":"1517","unstructured":null,"article-title":"Management of acute upper respiratory tract infection: the role of early intervention.","journal-title":"Expert Rev Respir Med","doi-asserted-by":"publisher"},{"DOI":"10.1164/rccm.202011-4239PP","key":"doi250038r27","year":"2021","issue":"2","author":"Behr","volume":"204","first-page":"142","unstructured":null,"article-title":"Latent tuberculosis: two centuries of confusion.","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/nrurol.2010.190","key":"doi250038r28","year":"2010","issue":"12","author":"Foxman","volume":"7","first-page":"653","unstructured":null,"article-title":"The epidemiology of urinary tract infection.","journal-title":"Nat Rev Urol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.crohns.2012.06.024","key":"doi250038r29","year":"2013","issue":"4","author":"Aubin","volume":"7","first-page":"257","unstructured":null,"article-title":"The complexity of adverse side-effects to biological agents.","journal-title":"J Crohns Colitis","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17318","key":"doi250038r30","year":"2019","issue":"2","author":"Langley","volume":"180","first-page":"306","unstructured":null,"article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250038r31","year":"2018","issue":"8","author":"Griffiths","volume":"17","first-page":"826","unstructured":null,"article-title":"Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0246-9","key":"doi250038r32","year":"2017","issue":"2","author":"Blauvelt","volume":"18","first-page":"273","unstructured":null,"article-title":"Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3).","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18484","key":"doi250038r33","year":"2020","issue":"6","author":"Kimball","volume":"182","first-page":"1359","unstructured":null,"article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2017.02.005","key":"doi250038r34","year":"2017","issue":"6","author":"Valenzuela","volume":"108","first-page":"550","unstructured":null,"article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.","journal-title":"Actas Dermosifiliogr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2017.06.153","key":"doi250038r35","year":"2017","issue":"5","author":"Blauvelt","volume":"77","first-page":"855","unstructured":null,"article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2020.1782817","key":"doi250038r36","year":"2022","issue":"2","author":"Griffiths","volume":"33","first-page":"848","unstructured":null,"article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.232","key":"doi250038r37","year":"2019","issue":"4","author":"Ryan","volume":"81","first-page":"AB55","unstructured":null,"article-title":"Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.042","key":"doi250038r38","year":"2017","issue":"3","author":"Reich","volume":"76","first-page":"418","unstructured":null,"article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa0810652","key":"doi250038r39","year":"2010","issue":"2","author":"Griffiths","volume":"362","first-page":"118","unstructured":null,"article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-020-00555-7","key":"doi250038r40","year":"2020","issue":"6","author":"Reich","volume":"21","first-page":"881","unstructured":null,"article-title":"Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20568","key":"doi250038r41","year":"2021","issue":"6","author":"Reich","volume":"185","first-page":"1146","unstructured":null,"article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v104.41053","key":"doi250038r42","year":"2024","issue":null,"author":"Errichetti","volume":"104","first-page":null,"unstructured":null,"article-title":"Patients with persistent mild psoriasis after treatment with ustekinumab achieved greater improvements in skin clearance and patient-reported outcomes after switching to guselkumab in the phase 3 NAVIGATE Trial.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1155/2022/2442603","key":"doi250038r43","year":"2022","issue":null,"author":"Feng","volume":"2022","first-page":null,"unstructured":null,"article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials.","journal-title":"Int J Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chom.2012.04.008","key":"doi250038r44","year":"2012","issue":"5","author":"Hernández-Santos","volume":"11","first-page":"425","unstructured":null,"article-title":"Th17 cells in immunity to Candida albicans.","journal-title":"Cell Host Microbe","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3386","key":"doi250038r45","year":"2020","issue":"3","author":"Reid","volume":"100","first-page":null,"unstructured":null,"article-title":"Psoriasis and treatment: past, present and future aspects.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2015.04.013","key":"doi250038r46","year":"2015","issue":"8","author":"Carrascosa","volume":"106","first-page":"638","unstructured":null,"article-title":"Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.","journal-title":"Actas Dermosifiliogr","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.1338","key":"doi250038r47","year":"2023","issue":"7","author":"Phan","volume":"159","first-page":"763","unstructured":null,"article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40261-017-0603-3","key":"doi250038r48","year":"2018","issue":"3","author":"Hu","volume":"38","first-page":"191","unstructured":null,"article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis.","journal-title":"Clin Drug Investig","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.03.035","key":"doi250038r49","year":"2023","issue":"3","author":"Cole","volume":"152","first-page":"783","unstructured":null,"article-title":"Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2023.1191782","key":"doi250038r50","year":"2023","issue":null,"author":"Navarro-Compán","volume":"14","first-page":null,"unstructured":null,"article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250038r24","year":"2025","issue":null,"author":"Taylor","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,10,1]]},"reference-count":50,"published-online":null,"references-count":50,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.2714","is_oa":false,"title":"Biopharmaceutical Switching in Psoriasis Treatment","updated":"2025-08-17T18:46:03+00:00","published_date":"2025-08-06","best_oa_location":null}},"created_at":"2025-09-19T17:59:11.167Z","updated_at":"2025-11-13T07:40:24.859Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"sample_size","value":"n=12,661","value_numeric":12661},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"warning","value":"Effect sizes compare outcomes at week 4 or study end to baseline rather than head-to-head between specific switching strategies.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"warning","value":"Safety outcomes show wide confidence intervals, indicating imprecision.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"warning","value":"The abstract does not report follow-up duration, individual drug data, switching protocols, or PROM results.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and meta-analysis of 24 RCTs (n=12,661) in adults with plaque psoriasis evaluating effectiveness and safety when switching from an initial biologic to another (within or across classes); searches through January 25, 2025. The prespecified primary end point was PASI 90; secondary outcomes included PASI 75/100, global assessments, BSA ≤1%, PROMs, and safety events.","key_result":"PASI 90 improved by week 4 vs baseline (OR 6.53; 95% CI 2.58-16.51) and by end point vs baseline (OR 28.61; 95% CI 12.89-63.47); PASI 75 (OR 11.11; 95% CI 5.95-20.75) and PASI 100 (OR 18.76; 95% CI 8.37-42.01) also improved. No differences were seen in serious AEs (OR 1.63; 95% CI 0.72-3.69), severe AEs (OR 1.40; 95% CI 0.61-3.26), or treatment-related AEs (OR 1.79; 95% CI 0.41-7.88); infection rates were highest when switching from anti–TNF-α to IL-23p19 (0.62%), IL-17A (0.54%), or IL-12/23p40 (0.39%).","limitations":"Authors note the need for larger patient cohorts and longer follow-up to confirm findings. The abstract does not detail follow-up duration, switching regimens, or PROM results, and safety estimates have wide CIs.","practice_takeaway":"For adults with plaque psoriasis who fail a biologic, switching—especially across classes—can yield high PASI responses without an observed increase in serious adverse events; monitor for infections, particularly after switching from anti–TNF-α to IL-23, IL-17, or IL-12/23 agents."}},{"doi":"10.1016/j.jaad.2025.07.031","pmid":"40683353","title":"Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2025-07-20T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2025.07.031","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-21","doi":"10.1016/j.jaad.2025.07.031","days":"14","issn":"0190-9622","rank":"8","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jaad.2025.07.031","title":"Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study.","journal":"Journal of the American Academy of Dermatology","methods":"","results":"","abstract":"","keywords":["chronic immunosuppression","malignancy risk of mycophenolate mofetil","mycophenolate mofetil","mycophenolate mofetil use in dermatology","mycophenolate mofetil use in organ transplant"],"pubmed_id":"40683353","conclusions":"","publication_date":"2025-07-20T00:00:00"},"crossref":{"DOI":"10.1016/j.jaad.2025.07.031","URL":"https://doi.org/10.1016/j.jaad.2025.07.031","ISSN":["0190-9622"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0190962225024843?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0190962225024843?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1327-1330","type":"journal-article","issue":"5","score":1,"title":["Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study"],"author":[{"given":"Robin C.","family":"Yi","sequence":"first","affiliation":[]},{"given":"Ainsley J.","family":"Ruley","sequence":"additional","affiliation":[]},{"given":"Aishwarya","family":"Sharma","sequence":"additional","affiliation":[]},{"given":"Matthew L.","family":"Hrin","sequence":"additional","affiliation":[]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[]},{"given":"Lindsay C.","family":"Strowd","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,11]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"93","created":{"date-time":"2025-07-17T15:24:03Z","timestamp":1752765843000,"date-parts":[[2025,7,17]]},"indexed":{"date-time":"2025-10-18T00:40:03Z","timestamp":1760748003930,"date-parts":[[2025,10,18]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000,"date-parts":[[2025,7,15]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0190962225024843"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study"},{"name":"journaltitle","label":"Journal Title","value":"Journal of the American Academy of Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jaad.2025.07.031"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc."}],"deposited":{"date-time":"2025-10-18T00:17:03Z","timestamp":1760746623000,"date-parts":[[2025,10,18]]},"issn-type":[{"type":"print","value":"0190-9622"}],"published":{"date-parts":[[2025,11]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/S0738-081X(02)00271-7","key":"10.1016/j.jaad.2025.07.031_bib1","year":"2002","issue":"5","author":"Assmann","volume":"20","first-page":"505","unstructured":null,"article-title":"New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.jaad.2025.07.031_bib2","year":"2011","issue":"1","author":"Park","volume":"4","first-page":"18","unstructured":null,"article-title":"The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room","journal-title":"J Clin Aesthet Dermatol","doi-asserted-by":null},{"DOI":"10.1016/j.trim.2022.101698","key":"10.1016/j.jaad.2025.07.031_bib3","year":"2022","issue":null,"author":"Shao","volume":"75","first-page":null,"unstructured":null,"article-title":"Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients","journal-title":"Transpl Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1600-6143.2004.00450.x","key":"10.1016/j.jaad.2025.07.031_bib4","year":"2004","issue":"6","author":"Kasiske","volume":"4","first-page":"905","unstructured":null,"article-title":"Cancer after kidney transplantation in the United States","journal-title":"Am J Transplant","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2008.08.049","key":"10.1016/j.jaad.2025.07.031_bib5","year":"2009","issue":"2","author":"Orvis","volume":"60","first-page":"183","unstructured":null,"article-title":"Mycophenolate mofetil in dermatology","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0190962225024843"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,11]]},"reference-count":5,"published-online":null,"references-count":5,"short-container-title":["Journal of the American Academy of Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jaad.2025.07.031","is_oa":true,"title":"Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study","updated":"2025-10-20T00:03:25+00:00","published_date":"2025-07-17","best_oa_location":{"url":"https://doi.org/10.1016/j.jaad.2025.07.031","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1016/j.jaad.2025.07.031"}}},"created_at":"2025-10-27T13:37:43.000Z","updated_at":"2025-11-03T07:01:44.169Z","tags":[{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"condition","value":"Generalized Pustular Psoriasis","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"warning","value":"A separate sirolimus vs tacrolimus dermatologic surgery cohort is described but reports no outcomes in the provided excerpt.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"warning","value":"Costs and utilization reflect 2016–2019 U.S. claims and may not generalize after billing changes or post-approval use of spesolimab.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2025.07.031","tag_type":"warning","value":"The provided title about mycophenolate and oncogenic risk is not addressed in the supplied text; no data on mycophenolate are available here.","value_numeric":null}],"summaries":{"what_studied":"A U.S. claims–based, propensity score–matched analysis (2016–2019) compared healthcare resource use and costs in adults with generalized pustular psoriasis (All-GPP n=633; subcohorts GPP+PsO n=344, GPP-only n=289) versus plaque psoriasis–only (n=633), excluding phototherapy-only claims; median follow-up was 2.7–2.9 years for GPP cohorts and 2.5 years for plaque PsO.","key_result":"GPP had higher median total visits (3.0–4.0 vs 2.0; P<.001), outpatient/office visits (3.0 vs 2.0; P<.001), and laboratory use (2.0 vs 1.0; P<.05); inpatient (34 patients) and ICU (1 patient) visits occurred only in GPP, and ER visits were more frequent (12 vs 1). Median total costs were higher with GPP ($174–$205 vs $103; P<.001) and outpatient/office costs were higher ($168–$198 vs $100; P<.001); among GPP, median inpatient cost was $144 (34 patients), ICU cost $84,407 (1 patient), and ER costs $58–$1,490 (12 patients) versus $160 (1 patient) in plaque PsO.","limitations":"Cohorts were defined by ICD-10 codes in a claims database subject to miscoding. HCRU and costs reflect 2016–2019 data, before billing changes and before approval of spesolimab for GPP flares.","practice_takeaway":"Adults with GPP use more healthcare and incur higher costs than those with plaque psoriasis; plan for greater outpatient, emergency, and occasional inpatient needs when managing GPP. Interpret these cost patterns in the context of pre-2020 coding and absence of IL-36–targeted therapy in this dataset."}},{"doi":"10.1001/jamadermatol.2024.2701","pmid":"39167366","title":"Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-08-21T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.2701","source_score":58,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-10-21","doi":"10.1001/jamadermatol.2024.2701","days":"30","issn":"2168-6068","rank":"4","field":"Clinical Medicine","score":"58","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.2701","title":"Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"In total, 259 patients were randomized and received treatment (mean [SD] age, 47 [13] years; 82 women [32%]). At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo. PASI 90 responses were consistent with PASI 75. PASI 100 demonstrated a dose response at all doses, with 17 patients (33%) achieving PASI 100 with zasocitinib, 30 mg. Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.","abstract":"$37","keywords":[],"pubmed_id":"39167366","conclusions":"","publication_date":"2024-08-21T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.2701","URL":"https://doi.org/10.1001/jamadermatol.2024.2701","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2822710/jamadermatology_armstrong_2024_oi_240030_1729089087.32264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1066","type":"journal-article","issue":"10","score":1,"title":["Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis"],"author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[{"name":"University of California, Los Angeles"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[{"name":"Lynde Institute for Dermatology and Probity Medical Research, Markham, Ontario, Canada"}]},{"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[{"name":"Innovaderm Research, Montreal, Quebec, Canada"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"ForCare Medical Center, Tampa, Florida"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine, Rockville, Maryland"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[{"name":"First OC Dermatology Research, Fountain Valley, California"}]},{"given":"Xinyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}]},{"given":"Nathalie","family":"Franchimont","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}]},{"given":"Esha A.","family":"Gangolli","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}]},{"given":"Jessamyn","family":"Blau","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}]},{"given":"Yiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}]},{"given":"Bhaskar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Nimbus Discovery Inc, Boston, Massachusetts"}]},{"given":"Graham","family":"Heap","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc, Cambridge, Massachusetts"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada"},{"name":"Department of Dermatology, University of Toronto School of Medicine, Toronto, Ontario, Canada"}]}],"issued":{"date-parts":[[2024,10,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-08-21T22:32:21Z","timestamp":1724279541000,"date-parts":[[2024,8,21]]},"indexed":{"date-time":"2025-09-13T15:29:53Z","timestamp":1757777393354,"date-parts":[[2025,9,13]]},"subject":[],"abstract":"$38","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2822710"}},"subtitle":["A Randomized Clinical Trial"],"deposited":{"date-time":"2024-10-16T15:07:31Z","timestamp":1729091251000,"date-parts":[[2024,10,16]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,10,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1007/s13555-022-00695-0","key":"doi240030r1","year":"2022","issue":"4","author":"Armstrong","volume":"12","first-page":"1055","unstructured":null,"article-title":"Impact of psoriatic disease on quality of life: interim results of a global survey.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0052935","key":"doi240030r2","year":"2012","issue":"12","author":"Armstrong","volume":"7","first-page":null,"unstructured":null,"article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00518-8","key":"doi240030r3","year":"2021","issue":"3","author":"Papp","volume":"11","first-page":"1053","unstructured":null,"article-title":"Psoriasis prevalence and severity by expert elicitation.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2017.07.004","key":"doi240030r4","year":"2017","issue":"3","author":"Hawkes","volume":"140","first-page":"645","unstructured":null,"article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1002/14651858.CD011535.pub2","key":"doi240030r5","year":"2017","issue":"12","author":"Sbidian","volume":"12","first-page":null,"unstructured":null,"article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1600-065X.2008.00754.x","key":"doi240030r6","year":"2009","issue":"1","author":"Ghoreschi","volume":"228","first-page":"273","unstructured":null,"article-title":"Janus kinases in immune cell signaling.","journal-title":"Immunol Rev","doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.aag1974","key":"doi240030r7","year":"2016","issue":"363","author":"Dendrou","volume":"8","first-page":null,"unstructured":null,"article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.","journal-title":"Sci Transl Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-018-25282-2","key":"doi240030r8","year":"2018","issue":"1","author":"Enerbäck","volume":"8","first-page":"7043","unstructured":null,"article-title":"The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1038/ng.2467","key":"doi240030r9","year":"2012","issue":"12","author":"Tsoi","volume":"44","first-page":"1341","unstructured":null,"article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.","journal-title":"Nat Genet","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0122271","key":"doi240030r10","year":"2015","issue":"4","author":"Diogo","volume":"10","first-page":null,"unstructured":null,"article-title":"TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.22631/rr.2018.69997.1057","key":"doi240030r11","year":"2018","issue":"4","author":"Faezi","volume":"3","first-page":"151","unstructured":null,"article-title":"Association of TYK2 rs34536443 polymorphism with susceptibility to systemic lupus erythematous in the Iranian population.","journal-title":"Rheumatology Research","doi-asserted-by":"publisher"},{"DOI":"10.1038/nature11582","key":"doi240030r12","year":"2012","issue":"7422","author":"Jostins","volume":"491","first-page":"119","unstructured":null,"article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14018","key":"doi240030r13","year":"2015","issue":"4","author":"Papp","volume":"173","first-page":"949","unstructured":null,"article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/ski2.133","key":"doi240030r14","year":"2022","issue":"1","author":"Lee","volume":"3","first-page":null,"unstructured":null,"article-title":"Oral Janus kinase inhibitors in the treatment of atopic dermatitis: a systematic review and meta-analysis.","journal-title":"Skin Health Dis","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2023.20351","key":"doi240030r15","year":"2023","issue":"6","author":"Liu","volume":"6","first-page":null,"unstructured":null,"article-title":"Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2021.790125","key":"doi240030r16","year":"2021","issue":null,"author":"Qi","volume":"12","first-page":null,"unstructured":null,"article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/keaa895","key":"doi240030r17","year":"2021","issue":null,"author":"Clarke","volume":"60","first-page":"ii24","unstructured":null,"article-title":"The safety of JAK-1 inhibitors.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40264-023-01333-0","key":"doi240030r18","year":"2023","issue":"11","author":"Yang","volume":"46","first-page":"1049","unstructured":null,"article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors.","journal-title":"Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1806382","key":"doi240030r19","year":"2018","issue":"14","author":"Papp","volume":"379","first-page":"1313","unstructured":null,"article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.07.002","key":"doi240030r20","year":"2023","issue":"1","author":"Armstrong","volume":"88","first-page":"29","unstructured":null,"article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.08.061","key":"doi240030r21","year":"2023","issue":"1","author":"Strober","volume":"88","first-page":"40","unstructured":null,"article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1021/acs.jmedchem.3c00600","key":"doi240030r24","year":"2023","issue":"15","author":"Leit","volume":"66","first-page":"10473","unstructured":null,"article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279.","journal-title":"J Med Chem","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.06.590","key":"doi240030r25","year":"2022","issue":"3","author":"McElwee","volume":"87","first-page":"AB139","unstructured":null,"article-title":"33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: results from a phase 1b trial of the novel allosteric TYK2 inhibitor NTX-973.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.c869","key":"doi240030r26","year":"2010","issue":null,"author":"Moher","volume":"340","first-page":"c869","unstructured":null,"article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1159/000250839","key":"doi240030r27","year":"1978","issue":"4","author":"Fredriksson","volume":"157","first-page":"238","unstructured":null,"article-title":"Severe psoriasis—oral therapy with a new retinoid.","journal-title":"Dermatologica","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"doi240030r28","year":"1994","issue":"3","author":"Finlay","volume":"19","first-page":"210","unstructured":null,"article-title":"Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000113150","key":"doi240030r29","year":"2008","issue":"3","author":"Revicki","volume":"216","first-page":"260","unstructured":null,"article-title":"Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2014.943687","key":"doi240030r30","year":"2015","issue":"3","author":"Viswanathan","volume":"26","first-page":"235","unstructured":null,"article-title":"Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.03.026","key":"doi240030r31","year":"2016","issue":"1","author":"Strober","volume":"75","first-page":"77","unstructured":null,"article-title":"Clinical meaningfulness of complete skin clearance in psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-020-00428-1","key":"doi240030r32","year":"2020","issue":"5","author":"Lacour","volume":"10","first-page":"1099","unstructured":null,"article-title":"Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL).","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(12)60642-4","key":"doi240030r33","year":"2012","issue":"9843","author":"Papp","volume":"380","first-page":"738","unstructured":null,"article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.12070","key":"doi240030r34","year":"2013","issue":"2","author":"Rich","volume":"168","first-page":"402","unstructured":null,"article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2022.05.325","key":"doi240030r35","year":"2022","issue":"8","author":"Gangolli","volume":"142","first-page":"S54","unstructured":null,"article-title":"317 Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240030r22","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Armstrong? A, Lebwohl? M, Warren? R, . Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results. Accessed January 8, 2024. https://acrabstracts.org/abstract/deucravacitinib-in-plaque-psoriasis-3-year-safety-and-efficacy-results/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240030r23","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Strober? B, Sofen? H, Imafuku? S, . Deucravacitinib in plaque psoriasis: maintenance of response over 3 years in the phase 3 POETYK PSO-1 and PSO-2 trials. Accessed January 8, 2024. https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2023/Psoriasis.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,10,1]]},"reference-count":35,"published-online":null,"references-count":35,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":18},"unpaywall":{"doi":"10.1001/jamadermatol.2024.2701","is_oa":true,"title":"Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis","updated":"2025-09-06T02:51:56+00:00","published_date":"2024-08-21","best_oa_location":{"url":"https://doi.org/10.1001/jamadermatol.2024.2701","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2024.2701"}}},"created_at":"2025-09-20T06:26:18.684Z","updated_at":"2025-09-20T06:32:50.058Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"generic","value":"zasocitinib","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"modality","value":"TYK2 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"sample_size","value":"n=259","value_numeric":259},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"warning","value":"Only short-term safety is reported; longer-term risks are unknown from this report.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"warning","value":"Secondary outcomes (e.g., PASI 90) are described qualitatively without numeric data in the provided text.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2701","tag_type":"warning","value":"Two different population counts are reported (287 randomized; 259 treated); the sample size tag reflects the treated population.","value_numeric":null}],"summaries":{"what_studied":"A phase 2b, randomized, double-blind, placebo-controlled trial across 55 North American sites tested oral zasocitinib 2, 5, 15, or 30 mg once daily vs placebo for 12 weeks in adults 18-70 with moderate to severe plaque psoriasis (PASI ≥12, PGA ≥3, BSA ≥10%; n=259 treated), followed by 4 weeks of follow-up. The primary endpoint was PASI 75 at week 12.","key_result":"At week 12, PASI 75 was achieved by 18%, 44%, 68%, and 67% with zasocitinib 2, 5, 15, and 30 mg vs 6% with placebo; PASI 100 occurred in 33% (17/52) at 30 mg. Treatment-emergent adverse events occurred in 53%–62% with zasocitinib vs 44% with placebo, with no dose dependency and no clinically meaningful lab changes reported.","limitations":"Short treatment (12 weeks) with only 4-week follow-up limits assessment of durability and safety. Placebo-only comparator and a modest treated sample size (n=259) restrict comparative effectiveness and generalizability.","practice_takeaway":"Zasocitinib ≥5 mg daily improved skin clearance vs placebo over 12 weeks in moderate to severe plaque psoriasis, with similar short-term safety and no lab signal. Findings are phase 2b and exploratory; clinical use awaits longer-term and head-to-head phase 3 data."}},{"doi":"10.1001/jamadermatol.2024.2463","pmid":"39083288","title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-07-31T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2024.2463","source_score":37,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-08-23","doi":"10.1001/jamadermatol.2024.2463","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"37","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.2463","title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"Overall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks/every 16 weeks; n = 148/n = 149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (P = .001), with 91.9% (137/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)-cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and β defensin (BD)-2 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified.","abstract":"$39","keywords":[],"pubmed_id":"39083288","conclusions":"","publication_date":"2024-07-31T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.2463","URL":"https://doi.org/10.1001/jamadermatol.2024.2463","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2821677/jamadermatology_eyerich_2024_oi_240026_1728397268.62533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"953","type":"journal-article","issue":"9","score":1,"title":["Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis"],"author":[{"given":"Kilian","family":"Eyerich","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany"}]},{"given":"Khusru","family":"Asadullah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin, Berlin, Germany"},{"name":"Dermatology Potsdam MVZ, Potsdam, Germany"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt am Main, Frankfurt, Germany"}]},{"given":"Peter","family":"Weisenseel","sequence":"additional","affiliation":[{"name":"Dermatologikum Hamburg, Hamburg, Germany"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Toulouse University, Toulouse, France"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, and Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany"}]},{"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, and Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany"}]},{"given":"Stefanie","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Center for Allergy and Environment, Technical University and Helmholtz Center Munich, Munich, Germany"}]},{"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[{"name":"Center for Allergy and Environment, Technical University and Helmholtz Center Munich, Munich, Germany"}]},{"given":"Julianty","family":"Angsana","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}]},{"given":"Friedemann J. H.","family":"Taut","sequence":"additional","affiliation":[{"name":"Taut Science and Service GmbH, Konstanz, Germany"}]},{"given":"Kristen","family":"Kohler","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}]},{"given":"Yanqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}]},{"given":"Jocelyn","family":"Sendecki","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}]},{"given":"Monica W. L.","family":"Leung","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}]},{"given":"Sven","family":"Wegner","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}]},{"given":"Yvonne","family":"Personke","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}]},{"given":"Mario","family":"Gomez","sequence":"additional","affiliation":[{"name":"Janssen Global Services LLC, Horsham, Pennsylvania"}]},{"given":"Nenja","family":"Krüger","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}]},{"given":"Sarah","family":"Tabori","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}]},{"given":"Knut","family":"Schäkel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases, Heidelberg University Hospital, Heidelberg, Germany"}]}],"issued":{"date-parts":[[2024,9,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-07-31T17:14:47Z","timestamp":1722446087000,"date-parts":[[2024,7,31]]},"indexed":{"date-time":"2025-09-19T08:02:55Z","timestamp":1758268975930,"date-parts":[[2025,9,19]]},"subject":[],"abstract":"$3a","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2821677"}},"subtitle":["The GUIDE Randomized Clinical Trial"],"deposited":{"date-time":"2024-10-09T15:27:26Z","timestamp":1728487646000,"date-parts":[[2024,10,9]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,9,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1038/nrdp.2016.82","key":"doi240026r1","year":"2016","issue":null,"author":"Greb","volume":"2","first-page":"16082","unstructured":null,"article-title":"Psoriasis.","journal-title":"Nat Rev Dis Primers","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)32549-6","key":"doi240026r2","year":"2021","issue":"10281","author":"Griffiths","volume":"397","first-page":"1301","unstructured":null,"article-title":"Psoriasis.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1177/24755303221127338","key":"doi240026r3","year":"2022","issue":"4","author":"Blauvelt","volume":"7","first-page":"157","unstructured":null,"article-title":"Resident memory T cells in psoriasis: key to a cure?","journal-title":"J Psoriasis Psoriatic Arthritis","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjopen-2021-049822","key":"doi240026r4","year":"2021","issue":"9","author":"Eyerich","volume":"11","first-page":null,"unstructured":null,"article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).","journal-title":"BMJ Open","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2022.2154570","key":"doi240026r5","year":"2022","issue":null,"author":"van der Schoot","volume":"2154570","first-page":null,"unstructured":null,"article-title":"National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.041","key":"doi240026r6","year":"2017","issue":"3","author":"Blauvelt","volume":"76","first-page":"405","unstructured":null,"article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.042","key":"doi240026r7","year":"2017","issue":"3","author":"Reich","volume":"76","first-page":"418","unstructured":null,"article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(19)31773-8","key":"doi240026r8","year":"2019","issue":"10201","author":"Reich","volume":"394","first-page":"831","unstructured":null,"article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19236","key":"doi240026r9","year":"2023","issue":"10","author":"Schäkel","volume":"37","first-page":"2016","unstructured":null,"article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2021.01.005","key":"doi240026r11","year":"2021","issue":"7","author":"Mehta","volume":"141","first-page":"1707","unstructured":null,"article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2019.05.016","key":"doi240026r12","year":"2019","issue":"12","author":"Gordon","volume":"139","first-page":"2437","unstructured":null,"article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2011.139","key":"doi240026r13","year":"2011","issue":"9","author":"Bovenschen","volume":"131","first-page":"1853","unstructured":null,"article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2014.01.025","key":"doi240026r14","year":"2014","issue":"4","author":"Sofen","volume":"133","first-page":"1032","unstructured":null,"article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ddg.14508","key":"doi240026r15","year":"2021","issue":"6","author":"Nast","volume":"19","first-page":"934","unstructured":null,"article-title":"German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 1: treatment goals and treatment recommendations.","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18333","key":"doi240026r16","year":"2020","issue":"5","author":"Mahil","volume":"182","first-page":"1158","unstructured":null,"article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2016.06.038","key":"doi240026r17","year":"2017","issue":"3","author":"Kolbinger","volume":"139","first-page":"923","unstructured":null,"article-title":"ß-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jcph.1063","key":"doi240026r18","year":"2018","issue":"5","author":"Yao","volume":"58","first-page":"613","unstructured":null,"article-title":"Population pharmacokinetic modeling of guselkumab, a human IgG1? monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis.","journal-title":"J Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19652","key":"doi240026r19","year":"2024","issue":"5","author":"Eyerich","volume":"38","first-page":"e424","unstructured":null,"article-title":"An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18143","key":"doi240026r20","year":"2020","issue":"2","author":"Reich","volume":"182","first-page":"304","unstructured":null,"article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40265-020-01448-z","key":"doi240026r21","year":"2021","issue":"3","author":"Michielsens","volume":"81","first-page":"349","unstructured":null,"article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review.","journal-title":"Drugs","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.15722","key":"doi240026r22","year":"2017","issue":"6","author":"Blauvelt","volume":"177","first-page":"1552","unstructured":null,"article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40261-023-01280-9","key":"doi240026r23","year":"2023","issue":"7","author":"Herranz-Pinto","volume":"43","first-page":"517","unstructured":null,"article-title":"Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation.","journal-title":"Clin Drug Investig","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2019.06.002","key":"doi240026r25","year":"2019","issue":"1","author":"Kurihara","volume":"95","first-page":"21","unstructured":null,"article-title":"Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course.","journal-title":"J Dermatol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17748","key":"doi240026r26","year":"2019","issue":"2","author":"Vo","volume":"181","first-page":"410","unstructured":null,"article-title":"CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-naïve nonlesional sites of psoriasis possibly in correlation with disease duration.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(21)00184-7","key":"doi240026r27","year":"2021","issue":"10275","author":"Ghoreschi","volume":"397","first-page":"754","unstructured":null,"article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18474","key":"doi240026r28","year":"2022","issue":"12","author":"Reich","volume":"36","first-page":"2393","unstructured":null,"article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator’s Global Assessment scores predict complete skin clearance.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240026r10","year":"2018","issue":null,"author":"Liu","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240026r24","year":"2022","issue":null,"author":"Kreuger","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,9,1]]},"reference-count":28,"published-online":null,"references-count":28,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":23},"unpaywall":{"doi":"10.1001/jamadermatol.2024.2463","is_oa":true,"title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis","updated":"2025-09-06T02:51:56+00:00","published_date":"2024-07-31","best_oa_location":{"url":"https://doi.org/10.1001/jamadermatol.2024.2463","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2024.2463"}}},"created_at":"2025-09-20T07:24:42.519Z","updated_at":"2025-09-20T07:24:42.519Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"sample_size","value":"n=297","value_numeric":297},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"warning","value":"Biomarker changes are described without numeric effect sizes in the abstract.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.2463","tag_type":"warning","value":"Only super responders were randomized; applicability to broader psoriasis populations is not addressed here.","value_numeric":null}],"summaries":{"what_studied":"A phase 3b randomized, double-blind comparison in adult “super responders” with moderate to severe plaque psoriasis tested guselkumab every 16 weeks versus every 8 weeks from week 28 to week 68. Super responders had PASI 0 at weeks 20 and 28; the primary end point was PASI <3 at week 68 with a 10% noninferiority margin.","key_result":"Noninferiority was met (P=.001): 91.9% (137/149; 90% CI, 87.3%-95.3%) on every-16-week dosing and 92.6% (137/148; 90% CI, 88.0%-95.8%) on every-8-week dosing had PASI <3 at week 68. Skin CD8+ tissue‑resident memory T cells and serum IL‑17A, IL‑17F, IL‑22, and BD‑2 decreased from baseline and stayed low in both groups through week 68; no new safety signals were identified.","limitations":"Only super responders were randomized; non–super responders continued open-label dosing and were not compared. Outcomes are reported through week 68 only.","practice_takeaway":"In adults who achieve complete clearance at weeks 20 and 28 on guselkumab, extending dosing to every 16 weeks maintained disease control to week 68 in about 92%, matching every‑8‑week dosing; no new safety signals emerged."}},{"doi":"10.1001/jamadermatol.2023.4990","pmid":"38117526","title":"Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2023-12-20T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2023.4990","source_score":86,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-01-18","doi":"10.1001/jamadermatol.2023.4990","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"86","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2023.4990","title":"Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"$3b","abstract":"$3c","keywords":[],"pubmed_id":"38117526","conclusions":"","publication_date":"2023-12-20T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2023.4990","URL":"https://doi.org/10.1001/jamadermatol.2023.4990","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2812729/jamadermatology_eichenfield_2023_oi_230061_1707346940.68612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"156","type":"journal-article","issue":"2","score":1,"title":["Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis"],"author":[{"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Diego, School of Medicine"},{"name":"Department of Pediatrics, University of California, San Diego, School of Medicine"},{"name":"Division of Pediatric and Adolescent Dermatology, Rady Children’s Hospital–San Diego, San Diego, California"}]},{"given":"Sanela","family":"Tarabar","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"ForCare Clinical Research, Tampa, Florida"}]},{"given":"Alfonso","family":"García-Bello","sequence":"additional","affiliation":[{"name":"Renaissance Research and Medical Group, Cape Coral, Florida"}]},{"given":"Gang","family":"Feng","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]},{"given":"Gerald","family":"Fetterly","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]},{"given":"Ping","family":"Mahling","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]},{"given":"Deepa E.","family":"Chandra","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Cambridge, Massachusetts"}]}],"issued":{"date-parts":[[2024,2,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2023-12-20T16:02:49Z","timestamp":1703088169000,"date-parts":[[2023,12,20]]},"indexed":{"date-time":"2025-09-04T13:15:25Z","timestamp":1756991725355,"date-parts":[[2025,9,4]]},"subject":[],"abstract":"$3d","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2812729"}},"subtitle":["A Randomized Clinical Trial"],"deposited":{"date-time":"2024-02-21T16:02:18Z","timestamp":1708531338000,"date-parts":[[2024,2,21]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,2,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1136/bmj.m1590","key":"doi230061r1","year":"2020","issue":null,"author":"Parisi","volume":"369","first-page":"m1590","unstructured":null,"article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2019.1655137","key":"doi230061r2","year":"2020","issue":"8","author":"Cork","volume":"31","first-page":"801","unstructured":null,"article-title":"Atopic dermatitis epidemiology and unmet need in the United Kingdom.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-019-0280-7","key":"doi230061r3","year":"2019","issue":"1","author":"Draelos","volume":"9","first-page":"71","unstructured":null,"article-title":"Tolerability of topical treatments for atopic dermatitis.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.07.087","key":"doi230061r4","year":"2021","issue":"2","author":"Elmets","volume":"84","first-page":"432","unstructured":null,"article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.03.023","key":"doi230061r5","year":"2014","issue":"1","author":"Eichenfield","volume":"71","first-page":"116","unstructured":null,"article-title":"Guidelines of care for the management of atopic dermatitis: section 2: management and treatment of atopic dermatitis with topical therapies.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-2051","key":"doi230061r6","year":"2015","issue":"5","author":"Åkerström","volume":"95","first-page":"587","unstructured":null,"article-title":"Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.3390/diagnostics11112090","key":"doi230061r7","year":"2021","issue":"11","author":"Moniaga","volume":"11","first-page":"2090","unstructured":null,"article-title":"The pathology of type 2 inflammation–associated itch in atopic dermatitis.","journal-title":"Diagnostics (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms222312793","key":"doi230061r8","year":"2021","issue":"23","author":"Singh","volume":"22","first-page":"12793","unstructured":null,"article-title":"The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications.","journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2018.01048","key":"doi230061r9","year":"2018","issue":null,"author":"Li","volume":"9","first-page":"1048","unstructured":null,"article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases.","journal-title":"Front Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2022.15632","key":"doi230061r10","year":"2022","issue":"11","author":"Lebwohl","volume":"328","first-page":"1073","unstructured":null,"article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.03.049","key":"doi230061r11","year":"2015","issue":"1","author":"Papp","volume":"73","first-page":"37","unstructured":null,"article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41573-021-00266-6","key":"doi230061r12","year":"2022","issue":"1","author":"Bieber","volume":"21","first-page":"21","unstructured":null,"article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.","journal-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2013.281053","key":"doi230061r13","year":"2013","issue":"20","author":"World Medical Association","volume":"310","first-page":"2191","unstructured":null,"article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1080/105294199277860","key":"doi230061r14","year":"1998","issue":"2","author":"Dixon","volume":"6","first-page":"65","unstructured":null,"article-title":"The International Conference on Harmonization Good Clinical Practice guideline.","journal-title":"Qual Assur","doi-asserted-by":"publisher"},{"DOI":"10.1111/biom.1999.55.issue-4","key":"doi230061r15","year":"1999","issue":"4","author":"Chan","volume":"55","first-page":"1202","unstructured":null,"article-title":"Test-based exact confidence intervals for the difference of two binomial proportions.","journal-title":"Biometrics","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.05.046","key":"doi230061r16","year":"2016","issue":"3","author":"Paller","volume":"75","first-page":"494","unstructured":null,"article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.36849/JDD","key":"doi230061r17","year":"2023","issue":"2","author":"Gooderham","volume":"22","first-page":"139","unstructured":null,"article-title":"The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: phase 2 proof-of-concept study.","journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12910-019-0395-5","key":"doi230061r18","year":"2019","issue":"1","author":"Strzebonska","volume":"20","first-page":"58","unstructured":null,"article-title":"Umbrella and basket trials in oncology: ethical challenges.","journal-title":"BMC Med Ethics","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi230061r19","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"FDA approves Arcutis’ ZORYVE™ (Roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals age 12 and older. Press release. Arcutis Biotherapeutics. 2022. Accessed July 29, 2022. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,2,1]]},"reference-count":19,"published-online":null,"references-count":19,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":10},"unpaywall":{"doi":"10.1001/jamadermatol.2023.4990","is_oa":true,"title":"Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis","updated":"2025-07-30T00:59:52+00:00","published_date":"2023-12-20","best_oa_location":{"url":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2812729/jamadermatology_eichenfield_2023_oi_230061_1707346940.68612.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2812729/jamadermatology_eichenfield_2023_oi_230061_1707346940.68612.pdf","url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2023.4990"}}},"created_at":"2025-09-20T09:19:29.896Z","updated_at":"2025-09-20T17:26:01.321Z","tags":[{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"sample_size","value":"n=104","value_numeric":104},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"warning","value":"Confidence intervals were reported at 90%, not 95%.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"warning","value":"The treatment period was only 6 weeks, limiting durability and safety conclusions.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.4990","tag_type":"warning","value":"Two conditions were studied within one trial; subgroup sizes were small, especially psoriasis (n=34).","value_numeric":null}],"summaries":{"limitations":"Short, 6-week phase 2a study with a total n=104 and a small psoriasis cohort (n=34). Only one concentration (0.01%) was tested, and results were reported with 90% CIs rather than 95% CIs.","what_studied":"A phase 2a randomized, double-blind trial at 34 sites in 4 countries tested once-daily PF-07038124 0.01% ointment vs vehicle for 6 weeks in adults (18–70 years) with mild to moderate atopic dermatitis (5%–20% BSA) or plaque psoriasis (5%–15% BSA). The primary outcome was percent change from baseline in EASI (AD) or PASI (psoriasis) at week 6.","key_result":"At week 6, PF-07038124 improved EASI in AD more than vehicle (LS mean CFB −74.9% vs −35.5%; difference −39.4% [90% CI −58.8% to −20.1%]; P<.001) and improved PASI in psoriasis more than vehicle (−4.8 vs 0.1; difference −4.9 [90% CI −7.0 to −2.8]; P<.001).","practice_takeaway":"Once-daily topical PF-07038124 0.01% outperformed vehicle at 6 weeks in mild to moderate AD and plaque psoriasis. TEAEs were similar to vehicle (AD: 25.0% vs 26.5%; psoriasis: 17.6% vs 35.3%), with no application site reactions on PF-07038124."}},{"doi":"10.1111/jdv.18812","pmid":"36478476","title":"Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2022-12-09T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.18812","source_score":375,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-02-03","doi":"10.1111/jdv.18812","days":"30","issn":"0926-9959","rank":"3","field":"Clinical Medicine","score":"375","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.18812","title":"Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"In the phase 2a trial, treatment with orismilast IR significantly improved the mean Psoriasis Area Severity Index score at week 16 compared to placebo. The phase 1 trial revealed comparable PK properties of the orismilast MR and IR formulations, with participants in the orismilast MR group experiencing fewer GI-related AEs than those receiving orismilast IR (16.7% vs. 33.3%).","abstract":"$3e","keywords":[],"pubmed_id":"36478476","conclusions":"Orismilast IR displayed higher efficacy compared to placebo in patients with moderate-to-severe psoriasis at week 16. Orismilast MR had similar PK properties and fewer GI disorders compared to the IR formulation in healthy participants. Future development of orismilast will be based on the MR formulation.","publication_date":"2022-12-09T00:00:00"},"crossref":{"DOI":"10.1111/jdv.18812","URL":"https://doi.org/10.1111/jdv.18812","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18812","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jdv.18812","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"711-720","type":"journal-article","issue":"4","score":1,"title":["Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets"],"author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[{"name":"Dermatology Centre Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester Manchester UK"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University and Central Connecticut Dermatology Connecticut New Haven USA"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences Washington District of Columbia USA"}]},{"given":"Emma","family":"Guttman","sequence":"additional","affiliation":[{"name":"Department of Dermatology Icahn School of Medicine at Mount Sinai New York New York USA"}]},{"given":"Philippe","family":"Andres","sequence":"additional","affiliation":[{"name":"UNION therapeutics A/S Hellerup Denmark"}]},{"given":"Jakob","family":"Felding","sequence":"additional","affiliation":[{"name":"UNION therapeutics A/S Hellerup Denmark"}]},{"given":"Deniz","family":"Tutkunkardas","sequence":"additional","affiliation":[{"name":"UNION therapeutics A/S Hellerup Denmark"}]},{"given":"Kim","family":"Kjøller","sequence":"additional","affiliation":[{"name":"UNION therapeutics A/S Hellerup Denmark"}]},{"given":"Morten O. A.","family":"Sommer","sequence":"additional","affiliation":[{"name":"UNION therapeutics A/S Hellerup Denmark"},{"name":"Novo Nordisk Foundation Center for Biosustainability Technical University of Denmark Kongens Lyngby Denmark"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital, Ludwig Maximilian University (LMU) Munich Munich Germany"},{"name":"Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami Florida USA"}]}],"funder":[{"id":[{"id":"10.13039/501100009708","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100009708","name":"Novo Nordisk Fonden","award":["NNF20CC0035580"],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2023,1,18]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"37","archive":["Portico"],"created":{"date-time":"2022-12-07T21:44:08Z","timestamp":1670449448000,"date-parts":[[2022,12,7]]},"indexed":{"date-time":"2025-09-20T20:42:49Z","timestamp":1758400969188,"date-parts":[[2025,9,20]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000,"date-parts":[[2023,1,18]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$3f","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.18812"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2022-08-18"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":1,"value":"2022-11-21"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":2,"value":"2023-01-18"}],"deposited":{"date-time":"2023-09-20T12:11:36Z","timestamp":1695211896000,"date-parts":[[2023,9,20]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2023,1,18]]},"publisher":"Wiley","reference":[{"DOI":"10.1016/S0140-6736(07)61128-3","key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.immunol.021908.132710","key":"e_1_2_10_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1084/jem.20041257","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cellsig.2016.01.007","key":"e_1_2_10_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.bjp.0702387","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.bjp.0702911","key":"e_1_2_10_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/archdermatol.2012.812","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-022-00712-0","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2000073","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fphar.2021.740803","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ClinicalTrials.gov.Identifier NCT02496546 an explorative trial evaluating the effect of LEO 32731 cream in adults with mild to moderate atopic dermatitis (AD).2017.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ClinicalTrials.gov.Identifier: NCT04982432 Orismilast for the treatment of mild to severe hidradenitis suppurativa (OSIRIS). Available from:https://clinicaltrials.gov/ct2/show/NCT04982432?id=NCT04982432&draw=2&rank=1&load=cart","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/bjd.18979","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_15_1","year":"2010","issue":"8","author":"Kurd SK","volume":"146","first-page":"891","unstructured":null,"article-title":"The risk of depression, anxiety, and suicidality in patients with psoriasis: a population‐based cohort study","journal-title":"Arch Dermatol","doi-asserted-by":null},{"DOI":"10.5114/ada.2018.75810","key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000365390","key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14164","key":"e_1_2_10_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.03.049","key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1096/fj.202001016RR","key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2147/CCID.S266036","key":"e_1_2_10_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1378/chest.12-2332","key":"e_1_2_10_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.06.056","key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.18812"],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"published-print":{"date-parts":[[2023,4]]},"reference-count":22,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2023,1,18]]},"references-count":22,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":21},"unpaywall":{"doi":"10.1111/jdv.18812","is_oa":true,"title":"Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets","updated":"2025-09-06T02:51:56+00:00","published_date":"2022-12-07","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.18812","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.18812","url_for_landing_page":"https://doi.org/10.1111/jdv.18812"}}},"created_at":"2025-09-22T07:56:22.026Z","updated_at":"2025-09-22T14:20:55.574Z","tags":[{"paper_doi":"10.1111/jdv.18812","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"generic","value":"orismilast","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"sample_size","value":"n=36","value_numeric":36},{"paper_doi":"10.1111/jdv.18812","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"warning","value":"Placebo denominator for PGA success was 17 due to missing data.","value_numeric":null},{"paper_doi":"10.1111/jdv.18812","tag_type":"warning","value":"This article reports both a phase 2a RCT and a separate phase 1 trial; design classification reflects the RCT but includes open-label PK components.","value_numeric":null}],"summaries":{"what_studied":"A phase 2a randomized, double-blind, placebo-controlled trial tested oral orismilast immediate-release 30 mg twice daily for 16 weeks in adults with moderate-to-severe plaque psoriasis (n=36). A single-site phase 1 study in healthy adults compared modified-release (MR) vs immediate-release (IR) pharmacokinetics, food effects, and short-term safety (single-dose parts; multiple-dose MR up to 60 mg twice daily for 17 days vs placebo).","key_result":"At week 16, mean PASI was 7.1 with orismilast vs 13.1 with placebo (LS mean difference −6.0; p=0.005); PASI-75 occurred in 8/18 (44.4%) vs 1/18 (5.6%), PGA success 7/18 (38.9%) vs 1/17 (5.6%), and DLQI improved by −9.1 vs placebo (3.8 vs 12.9; p=0.008). GI adverse events were frequent with IR (16/18, 88.9%; nausea 11/18, 61.1%; diarrhoea 9/18, 50.0%), leading to withdrawals in 9/18 (50.0%); in phase 1, MR and IR had similar PK, and GI AEs were lower with MR vs IR after single 30 mg doses (16.7% vs 33.3%; nausea 0% vs 27.8%).","limitations":"Small, single-centre phase 2a trial with high discontinuation (55.6% in orismilast IR; 50.0% in placebo) and LOCF imputation may bias efficacy estimates. Phase 1 findings were in healthy volunteers with small cohorts and included open-label parts; multiple-dose MR safety was short (17 days).","practice_takeaway":"Orismilast IR improved psoriasis signs but caused frequent GI AEs and high dropout; further development shifts to an MR tablet that kept similar exposure with fewer GI AEs after single dosing. Until larger patient trials with MR are complete, use remains investigational."}}],"initialOffset":17,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Plaque Psoriasis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Plaque Psoriasis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Plaque Psoriasis"}}}]]

Papers